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ABSTRACT
Six serial passages of a cell-adapted strain of EIAV were conducted 
in Shetland ponies. The 16 recipient ponies became agar-gel 
immunodiffusion test positive by 25 days after inoculation, and it was 
observed that the virulence of this cell-adapted strain increased 
through the successive passages. Clinical signs were closely monitored 
and recorded, and macroscopic as well as microscopic lesions of EIA were 
also recorded and evaluated. The effect of EIAV upon blood components 
was determined after several of the febrile episodes, and the effect of 
the immunosuppressant dexamethasone on infected ponies was also studied. 
EIAV was isolated in fetal equine kidney cells cultures from 90% of 
plasma samples collected during febrile episodes and from 51% of plasmas 
collected at afebrile periods.
The cross serum-neutralization test was carried out for EIAV 
isolates and sera collected from two experimental ponies. It was found 
that serum collected shortly after EIAV isolation did not neutralize the 
virus isolate, but the serum neutralizing activity increased in samples 
collected thereafter. None of the sera showed neutralizing activity 
against EIAV isolated after their collection. These results suggest an 
antigenic change in EIAV occurring in the pony which would allow for the 
virus persistence in its host.
Finally, a study was also carried out to determine whether the 
mixed culture cytopathogenicity assay, the syncytia infectivity assay, 
and the reverse plaque assay would be suitable to quantitate EIAV.
These assays have been successfully used to titrate several murine 
leukemia viruses, bovine leukemia virus, and several strains of hog
cholera virus respectively, 
be accurate and reliable to




Equine infectious anemia is one of the most important diseases of 
horses as it is present in almost any country in which horses are 
raised, causing heavy losses to the equine industry. Equine infectious 
anemia is one of the oldest viral diseases known to affect members of 
the Family Equidae.
The chronicity of the disease and the appearance of febrile 
relapses after the first febrile episode, have been the hallmark of 
equine infectious anemia, but also a puzzle for researchers who have 
attempted to explain why the horse remains an equine infectious anemia 
virus carrier forever, despite a normal immune response, and why the 
febrile relapses occur. It has been suggested that the periodic attacks 
of equine infectious anemia occur in concert with the generation and 
spread of novel strains of the virus, with the property to circumvent the 
host immune response and, consequently, to maintain a persistent 
infection in its unique host. So far, the nature of that antigenic 
variation in equine infectious anemia virus remains unknown.
It is the purpose of this research to generate sequential equine 
infectious anemia virus isolates for further serological and biochemical 
characterization that would lead in the near future to disclosure of the 
nature of the antigenic variation of equine infectious anemia virus and, 
therefore, to the preparation of immunoprophylactic or immunochemical 





The Generation of Virus Variant Candidates
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INTRODUCTION
Equine infectious anemia (EIA) is one of the most important
diseases of horses as it affects a large number of members of the Family
Equidae throughout the world, causing deaths, abortions, and low
performance of chronically infected individuals. Similarly, the
recurrent character of this disease has been a real challenge for
researchers. The way the etiological agent is believed to escape the
host immune response presents a real obstacle for the development of a
effective immunogen against the disease; however, the fact that equine
infectious anemia virus (EIAV) does not infect any other animal species^
is an important factor in its eventual future control. Finally, as EIA
is a widespread disease, it has been known by several synonyms such as
swamp fever, equine malarial fever, pernicious anemia, American surra,
2slow fever, mountain fever, and typhoid fever of horses.
The name "swamp fever" was given in the past to stress the belief
that the disease was more prevalent in animals pastured in low-lying
areas, but actually, the disease is present in horses living at high
altitudes (9000 feet above sea level). EIA has been known to exist in
the United States for about 80 years and statistics compiled by the
United States Department of Agriculture show that the highest percentage
of samples testing positive in the United States originated in 
3Louisiana. It was found that from January 1971 to December 1974, the 
prevalence rates ranged from 24.1% in 1971 (n = 3,465) to 12.7% in 1974 
(n = 8,996) and that EIA was more prevalent in the southwestern parishes 
(33.7% of 1,511 samples were positive) and that the lowest rate was 
observed in samples originating from horses in Orleans parish (3.8% of
3
1,147 samples were positive). In 1975, a survey was conducted in East
Baton Rouge Parish to determine the prevalence of EIA by the agar gel
immunodiffusion (AGID) test finding that 6.7% of the horses were 
4infected. In addition, according to statistics compiled by the U.S.
Department of Agriculture for fiscal years 1972 through 1975, antibodies
to EIAV were 4 to 6 times more prevalent in samples from horses in the
gulf coast states of Texas, Louisiana, Mississippi, Alabama, and Florida
3than elsewhere in the the United States.
The incidence of EIA was determined by Orrego et̂  ail.̂  in a band of 
horses experiencing an outbreak of the disease in 1976, where 11 horses 
had died due to EIA and 44.4% (36 out of 81) of the horses were positive 
reactors in the AGID test. A second test was carried out six months 
after the first examination and nine new positive horses were found, 
which meant that the incidence of the disease was 36% in that group of 
horses for the specified period of time. The remaining negative horses 
were tested by the AGID test every two months thereafter, finding that 
the incidence of the disease was 27% from April to June 1977 and 7.7% 
from July to September 1977. No new cases were detected between October 
1977 and June 1978, probably due to the elimination of the positive 
reactors. The same authors, at the same time, carried out a survey in 
horses from the rural and urban areas near the investigated outbreak and 
found that both the prevalence and the incidence of EIA was much lower 
in these populations than in bands of horses raised under conditions of 
high density.
5
THE ETIOLOGY OF EQUINE INFECTIOUS ANEMIA
The etiological agent of EIA is a virus from the Family
Retroviridae, Subfamily Lentivirinae (from the Latin, Lenti = slow).
Hence, the virus is an RNA virus related to tumor viruses (Oncovirinae 
6 8and Spumavirinae ’ ), yet, in the properties of the virus particle, EIAV
resembles visna, maedi, and progressive pneumonia viruses more than
other viruses from the family.
CHARACTERISTICS OF EIAV
Equine infectious anemia virus is spherical, enveloped, and the
virion has a diameter of 80 to 100 nm. The icosahedral capsid contains
9a heavy molecular weight RNA genome (60 to 70 S) composed of subunits.
£
The virus density is between 1.16 and 1.18 g/cm3 in sucrose gradients.
EIAV, like prototype retroviruses, matures by budding from external and
internal cytoplasmic membranes^’**', displays a complex morphology
12characteristic of type C viruses , and contains a reverse transcriptase 
6,13enzyme.
According to Matthews^, viruses from the family Retroviridae
contain about 60% protein, 35% lipid, and 3.5% carbohydrate by weight.
9The polypeptide composition of EIAV was determined by Parekh et al. , by 
using purified radioactive leucine or glucosamine-labeled EIAV of the 
cell-adapted Wyoming strain by two procedures: guanidine hydrochloride
gel filtration (GHCL-GF) and sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). By the first procedure, the chromatographic 
analysis of the radioactive EIAV revealed six distinct peaks of 
radioactivity, as follows: the first protein(s) to elute from GHCL-GF
were contained in the void volume fractions of the column indicating an 
apparent molecular weight of at least 100,000. The next EIAV protein
6
eluted as a relatively broad peak with an apparent molecular weight of 
about 74,000. This component was followed by the major EIAV structural 
polypeptide (p26) which displays a molecular weight of 26,000, and in 
succession, by three additional components of 15,000 (pl5), 11,000 
(pll), and 9,000 (p9) molecular weight, respectively. By the SDS-PAGE, 
four major low molecular weight polypeptides (p26, pl5, pll and p9) were 
revealed and in addition, other heavy molecular weight components were 
resolved, which included two polypeptides of 90,000 (gp90) and 45,000 
(gp45) molecular weight which were glycosylated, and four minor 
non-glycosylated proteins designated as p70, p61, p30, and p23. From 
the same study, the authors also concluded that EIAV and Friend murine 
leukemia virus (FLV) contain remarkably similar structural components, 
but they do slightly differ in the apparent molecular weight of their 
polypeptides.
CLINICAL DISEASE
Horses infected with EIAV have a variable clinical disease course.
The prominent signs include pyrexia, depression, weight loss, and 
14anemia. The incubation period in most experimentally infected horses 
is less than 30 days, but it is dose dependent and may extend to 90 days 
in horses receiving small quantities of virus by the subcutaneous 
route. ^  Kemeny £t aLl.'*'̂  reported that the incubation period 
following subcutaneous inoculation of infective serum varied inversely 
with the dose increasing from 6 days with 100 ml to 23 to 30 days with 
1.0 ml of a 10  ̂dilution of the same serum.
The most characteristic clinical sign is pyrexia which usually 
lasts 3 or 4 days, although it may last several weeks in some animals.
During any episode of clinical disease, the animal may die. Most horses
survive the first febrile episode and subsequently experience multiple
exacerbations of clinical disease, which are interspaced by several days
or weeks of clinical normality. This type of clinical course is the
most common in experimentally infected horses. After weeks or months of
recurring clinical disease, the animals may become quiescent and not
show signs for months or years. Animals that have been apparently
normal for a year or more may suddenly reexperience an acute febrile
episode. All horses have persistent viremia regardless of this clinical 
1  ̂20 22course. ’ 5 Thus, the spectrum of disease extends from acute
14disease, resulting in death, to asymptomatic carriers.
Once a horse is infected with EIAV, it is thought to remain a
20carrier of the virus for life. Several investigators have tested
blood from infected horses systematically over a period of 12 to 18
years and have consistently found the blood to be infectious for
23-25susceptible horses. Early workers assumed that the persistence of
EIAV in the blood stream of an infected horse resulted from a lack of an
immunological response by the host to the invading agent; however, it
has been proven that concept was misleading and that, in fact, the body
produces an abundance of certain types of specific antibody as a result
20of exposure to EIAV.
Acute EIA is most often associated with the first exposure to the 
virus, with fever and hemorrhages evident from 7 to 30 days after 
infection. Acute disease is thought to be associated with massive virus 
replication in and destruction of infected macrophages. Horses in the 
initial phase of acute EIA will be seronegative because the immune
8
system has had insufficient time to respond to the viral antigen.
During the peak of the febrile response with acute EIA, viremia of 10^
horse infectious doses/ml of whole blood is often found and EIAV antigen
may be extracted from splenic tissue at that time. The initial acute
phase of EIA infection may not be seen by the veterinarian unless there
is an epizootic of the infection in a groups of horses. Even then, the
horses must be under close supervision before the initial fever and
anorexia are detected. Neither anemia nor edema are seen at this 
8stage.
The more classical clinical signs of chronic EIA are loss of
weight, anemia, and edema which are seen later during recurring cycles
of the illness and which appear at biweekly intervals. The frequency
and severity of clinical episodes in horses with chronic EIA usually
decline with time, about 90% of them occurring within one year of 
22infection. The earliest deaths due to EIA usually do not occur until
4 weeks after infection. Horses with subacute and chronic EIA will be
seropositive. The EIAV titer in horses with chronic EIA varies but it
is highest during the periodic febrile episodes. Chronically infected
26 27horses have the most marked microscopic lesions. ’ The periodic
flare-ups of chronic EIA may be due to the production and release of
novel antigenic strains of virus, which are not neutralized by existing 
22antibodies. The subtle changes in the phenotype of EIAV have been 
referred to as "antigenic drift" and may occur because of minor
O  1 9 0
mutations in EIAV-RNA. *
Many of the clinical signs in horses with EIA may be referable to
26changes induced by immune reactions to viral products. An example of
this may be the anemia associated with EIAV infection. The pathogenesis
of the anemia has not been elucidated, but since EIAV possesses a 
29 30hemagglutinin 5 , virus may attach to erythrocytes and specific
antiviral immunoglobulins then attach to viral proteins. The immune
complexes on the cell surface would then attract complement. Complement
31 33coated erythrocytes are found in anemic EIAV-infected horses 5 and
3 /
the affected erythrocytes are then phagocytized by leukocytes.
Finally there is an important form of EIA in a high percentage of EIAV 
infected horses which are detected by the AGID test, i.e., horses that
do not show clinical illness associated with the infection, but do have
. _ „ . - 8,20,35a persistent infection.
The hallmark of chronic EIAV infection is the periodic appearance
36of clinical episodes of the disease which, according to Kono , are due 
to the formation of novel strains of EIAV that make possible the 
persistence of the virus in its host, despite a normal host immune 
response. These changes in the antigenicity of the virus are known as 
"antigenic drift" which is considered in the following.
The Case of Antigenic Drift - In various viral diseases like visna 
of Ovidae and EIA of Equidae, it has been found that, despite a normal 
host immune response to the viral infection, the individual remains 
infected for years. One mechanism, known as antigenic drift, by which 
these viruses produce antigenic variants allows the virus to temporarily 
escape from previously formed neutralizing antibody and from the cell 
mediated immune response. Changes in antigenicity are better known in 
other viruses as influenza virus, in which the B and C strains are
38believed to undergo less antigenic variation than the A strain. It
seems that the variability of human influenza viruses involve several
mechanisms that lead to the emergence of different subtypes (by
reassortment of surface protein genes between different strains,
possibly involving animal strains), to variation within subtypes by
point mutations occurring in genes coding for surface, as well as for
nonsurface proteins, or by deletions and insertions in genes coding for
38hemagglutinins and neuranimidases. Yet, the reassortment of genes
(genetic recombinations) induces major changes in the virus antigenicity
which are recognized as "antigenic shift." These antigenic shifts occur
at long intervals of time (several years) and may involve recombination
39and genetic interchange between a human and an animal influenza virus.
Some other viruses, like foot and mouth disease virus, vesicular
stomatitis virus, rabies virus, and polio virus, undergo antigenic
variations attributed to either persistence or high input short-term
infections which can provide conditions in which the inherent high
mutation rates of RNA viruses are reflected in high rates of genome 
28changes. Antigenic drift, on the other hand, is believed to occur due
28 38to accumulation of point mutations ’ , which are cumulative, and
38sequential changes in the nucleotides that lead to changes in the
amino acid sequences and therefore to antigenic variation.
In addition to antigenic variation in several viruses, antigenic
variation in human and animal trypanosomes has been also well studied;
as a matter of fact, humans and domestic animals infected with
pathogenic African trypanosomes normally do not survive infection even
40though immune responses are mounted against parasite antigens.
11
Furthermore, in the case of trypanosomes, the mechanism for the
formation of new antigenic variants of the parasite corresponds to the
expression of biochemically and serologically distinct variant specific
surface antigens (VSSA) which arise by direct mutation under immune
pressure, but the intimate mechanism that triggers the antigenic
variation is left unexplained. Nevertheless, it might be that virus
28variants arise due to RNA genome mutations and a population 
equilibrium is established. When that equilibrium is disrupted because 
of cell mediated immune pressure (infected cells are recognized and 
destroyed), some of the variants would be destroyed but some, or at 
least one, would escape the host immune response and would multiply, 
becoming the predominant strain. Antibody would be made against the 
novel strain of the virus and the horse would remain apparently normal 
for an unpredictable period of time before suffering a new febrile
episode due to the generation and replication of a new EIAV variant.
21Kono et̂  al. , with the aim of studying the antigenic variation of 
EIAV, inoculated 5 horses (subcutaneously) with a suspension containing 
10^ TCID^q of a "cloned" virus known as V70; as a result, all the 
recipient horses became AGID test positive by 24 post-inoculation day 
(PID), experienced the first febrile attack between 18 and 40 PID, and 
had an average of 3 febrile relapses during 155 days of observation. In 
addition, the infectivity of sera collected at the time of febrile 
relapses was found to fluctuate between 10'*"̂  and 10̂ '"* TCID^q of 
EIAV/0.5 ml. The neutralization activity of the sera collected from the 
same horse, at each one of the febrile episodes was tested against the 
virus isolated from the same material and against the parental virus
12
(inoculum, V70). The results showed that sera collected before 
inoculation and on 20 PID did not have neutralizing activity against any 
of the virus isolates (virus was isolated on PID 20, 44, 62, 83, and 
155), while some neutralizing activity against the parental virus and 
the first virus isolate was detected in serum collected at 40 PID. On
the contrary, sera collected at 62, 83, and 155 PID, failed to 
neutralize their correspondent virus isolate, but did neutralize all the 
virus isolates formed before serum collection. Equally important, the
tested sera did not neutralize any virus isolated after their 
collection.
21In another phase of Kono’s work , he tried to demonstrate the
immunological specificity of 5 viruses sequentially isolated from pony
£
number 493, and 5 horses were inoculated with 10 TCID^q of the "cloned" 
isolates EIAV subcutaneously. The sequential virus isolates were 
reacted with sera collected from the same pony at different times after 
inoculation, and as a result it was reported that the neutralizing 
effect of the sera was not restricted to the respective homologus 
isolates only, but overlapped to viruses preceding or following them in 
the sequence of isolates. This result is not consistent with the 
neutralization data from Kono's inoculations with "V70" and suggests 
that some antigenic determinants are common between the EIAV variants.
Finally, the antigenic stability of one of the virus isolates was 
tested at different times in horse leukocyte culture by using homologus 
and heterologus antisera and, as a result, each passaged virus
13
21showed the same and unaltered serological reactivity.
Gutekunst est ail. ̂  carried out a work with EIAV by using the equine
dermal cell-adapted strain of the virus, which was adapted by 
45Malmquist with the purpose of determining whether the virulence of 
this strain of EIAV would be modified by 200 passages in tissue culture 
when inoculated into ponies, would induce immunity against the disease, 
would revert to virulence in vivo, or would undergo antigenic alteration 
in the host. It was found that the onset of febrile response came later 
in ponies inoculated with high passaged EIAV than in ponies inoculated 
with low passaged EIAV (8 PID for EIAV passaged 2 times, and 121 PID for 
EIAV passaged 200 times); in addition, the authors found a correlation 
between number of passages and kinetics of positive AGID test samples.
Three of the four ponies inoculated with EIAV passaged 200 times 
had two to five intermittent febrile responses, beginning 70 to 126 PID. 
Each febrile response lasted 3 to 6 days and peak temperatures were 
between 38.6 and 41.5°C. One of the ponies had no increase in 
temperature before 202 PID. All became AGID test positive from 36 to 49 
PID. Equine infectious anemia virus was isolated from primary pony 
leukocyte cultures at varied intervals from three of four ponies having 
intermittent febrile responses, yet, from one of the ponies the virus 
was isolated only once.
The cross-neutralization test carried out with the virus isolated, 
yielded expected results, i.e., neutralization did not occur with serum 
collected before EIAV inoculation, the sera collected at the time of 
virus isolation showed a low level of neutralization, which increased in 
subsequently collected serum samples. Finally, the virus isolates did
14
grow in pony leukocyte culture, known to support the propagation of wild 
types of EIAV.
TRANSMISSION OF EQUINE INFECTIOUS ANEMIA
The most important means of natural transmission of EIAV is the
transfer of blood from the infected horse by blood feeding insects,
especially horse flies and deer flies. The virus will be transmitted
from one horse to another only when the feeding of the vector has been
interrupted and the vector has to complete its meal in a different 
46horse. So, even though both virus and horse flies are abundant, if 
the horse flies complete their blood meal on one horse there will be no 
transmission.
The mechanical transmission of EIAV by Tabanus fuscicostatus was 
47investigated and as a result, in 1 of 7 transmission trials, a single
horse fly transmitted EIAV from an acutely infected pony to a
susceptible pony. It was also found that groups of horse flies isolated
for 3, 10, or 30 minutes before refeeding transmitted EIAV, whereas
those isolated for 4 or 24 hours did not. In another work by Hawkins ej: 
48al. , all the attempts to mechanically transmit EIAV by T̂.
fuscicostatus to Shetland ponies from acutely infected donors were
successful, even with a low number of fly bites. All mechanical
transmission attempts from chronically infected ponies and biological
transmission attempts from acutely infected ponies, however, were
unsuccessful. Interestingly, transmission of EIAV by 1?. sulcifrons and
49Stomoxys calcitrans had been reported by earlier workers. There seems 
to be sufficient evidence to indicate that the disease may spread from 
one animal to another by simple contact, without the intervention of
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insects (from contaminated food or water) or from infected animal 
secretions.^ However, Kono et al.~^ were unable to isolate EIAV from 
urine and feces of 4 horses acutely infected with the virus. Equine 
infectious anemia virus is actually transmitted to susceptible horses by 
careless use of hypodermic needles, syringes, tatooing instruments, and 
other piercing tools.^ Williams et al.^ detected EIAV on hypodermic 
needles held at 25 C for 96 hours, but the virus was not detected 120
g
hours after the needles were dipped in solution of EIAV (10 TCID^Q/ml).
On the other hand, iji utero transmission of EIAV also occurs according
20 52to Coggins and Kemen et_ al. who found that 25% of the foals from
infected mares get infected in utero and usually die shortly after
birth.
DIAGNOSIS OF EQUINE INFECTIOUS ANEMIA
Equine infectious anemia can be only suspected on the basis of a
clinical history. Hence, laboratory procedures are used to detect EIAV
from a variety of sources, and EIAV antibody from the serum of test
horses. The complement fixation test (CFT) was one of the first tests
53to be used to detect EIAV antibody , but it has not been satisfactory 
for the diagnosis of EIA because IgG(T) in the horse does not readily 
fix complement (IgG fixes equine complement by the classic pathway 
originating at Cl, but IgG(T) does not); yet, IgG(T) does not interfere 
with the AGID test)."^’̂ "* The serum neutralization test has been used 
as a research tool^*^*^, but has limited usefulness in the diagnosis
g
of EIA. The same can be said of the hemagglutination-inhibition
test‘d, while serologic tests such as fluorescent antibody'^’"^,
58radioimmunoassay , and enzyme immunoassay have been utilized to detect 
EIAV or EIAV antibody. These tests are more sensitive than the AGID
16
test (as they detect minute amounts of antigen or antibody), but appear 
to be less specific.. Thus, they might be an aid for detection when 
antigen or antibody concentrations are low, which would yield a negative
O
AGID test.
The AGID test has been the most useful test for the diagnosis of 
EIA"^’̂  as it accurately and reliably detects EIAV antibody. In fact, 
a correlation between precipitating antibody and EIA viremia has been 
demonstrated."^ Nakajima et al.̂  studied the suitablility of 
AGID test antigen for the diagnosis of EIA based on the following
i
assessable considerations: (i) the antigen must be identical in its
reactivity with an antigen prepared from highly purified EIAV; (ii) the 
antigen reacts identically against serum samples from horses infected 
with any strain of EIAV; (iii) the antigen forms only one distinct 
precipitation line against reference positive serum; (iv) the antigen 
reacts with any serum samples which contain precipitating antibodies 
ranging from high and low levels of antibody titer; and (v) the antigen 
does not show any specific reaction against serum samples from 
noninfected horses. On the other hand, many studies have been conducted 
and reported concerning the protocols for the AGID test‘d  and the 
test has been a valuable tool for the diagnosis of EIA as well as to
determine the presence of the infection in many countries throughout the
3,4,5,61,62,67 TT . . ...world. However, the test has some limitions: (i) no
acute or early stages of the disease are detected; (ii) foals nursing
from infected dams may give a false positive result; (iii) chronically
infected horses may yield a negative test, and (iv) adequate experience
is required to interpret the test results.
The diagnosis of EIA can be assisted by clinical pathological 
procedures and by pathological alterations. In fact, clinical 
pathological alterations are related to the activity of the disease in a 
horse'*', while asymptomatic carriers have few detectable changes. The 
packed-cell volume and red blood cell counts decline during active 
disease. Siderocytes are found in variable numbers and the
white blood cell counts vary, but associated with a decrease is a 
relative lymphocytosis as a result of a decrease in granulocytic type 
cells.
The most marked gross pathologic lesions are splenomegaly,
lymphadenopathy, accentuated hepatic lobular structure, anemia,
26widespread hemorrhages, edema, and emaciation. Microscopically, there 
is marked lymphoid and reticuloendothelial cell proliferation, and 
infiltration occurs in the periportal and perisinusoidal areas of the 
liver. The Kupffer cells increase in number, become enlarged, and many 
contain hemosiderin. Proliferative glomerulitis characterized by 
irregular granular deposits of globulin and complement along the 
basement membrane and in the mesangial areas occurs in infected 
horses.^
EFFECT OF ADMINISTRATION OF IMMUNOSUPPRESSIVE DRUGS
As the mechanism of cellular immunity participates in the
prevention or recurrence of EIA or in immunity against the disease,
administration of an agent which causes a decrease in the number of
lymphocytes or the cells controlling this mechanism of immunity, will
induce the recurrence of the disease in horses clinically recovered or
35suffering from chronic EIA. Treatment with dexamethasone (DM) is
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68 69known to suppress cellular immunity, as well as humoral immunity. *
In fact, according to a number of studies, DM treatment causes a
remarkable decrease in number of lymphocytes in the circulation^
35but has no effect on serum antibody titer.
22Kono injected DM intramuscularly at the dosage of 5 mg/100 lb of 
body weight, daily for 5 consecutive days into 2 healthy horses, 3 
horses suffering from chronic infection, and 4 horses clinically 
recovered from chronic infection. All the infected horses failed to 
show a decrease in total leukocyte count of the circulating blood, but 
manifested a marked decrease of lymphocytes, particularly in lymph 
nodes, lymphoid follicles of the spleen, and lymphatic apparatus of the 
intestine. The two healthy controls and one clinically recovered horse 
presented no symptoms at all, while the other six horses exhibited 
pyrexia, anemia, the appearance of sideroleukocytes, and viremia as
observed at the time of spontaneous recurrence of fever.
35Kono ££ al. carried out a total of 12 experiments with seven 
infected and three healthy horses. In eight experiments with six 
infected horses, a rise of body temperature occurred 6 to 8 days after 
the beginning of DM treatment. A severe fever persisted for 4 to 9 days 
in five experiments, and a moderate fever for 1 to 2 days in the other 
three experiments. The remaining infected (one horse) and three healthy 
horses showed no symptoms. It was also observed that there was no 
difference in severity of fever or incubation period after the treatment 
between horses which had remained asymptomatic for 143 to 934 days after 
the last recurrence, and those which had shown short afebrile periods 
lasting for one month or less each. In the same experiment, in horses
suffering from fever the virus appeared in the serum immediately before 
or simultaneously with a febrile attack, and disappeared soon after 
pyretolysis. No virus could be recovered from one infected horse not 
manifesting EIA clinical signs, and from any of the three healthy 
horses. These results would indicate that the response to DM treatment 
varies in horses chronically infected with EIAV and that the depression 
of the cell mediated immune system leads to recurrence of EIA; 
therefore, treatment of EIAV infected horses with corticosteroids should 
be avoided, whereas immunosuppressive drugs may be useful as a research 
tool in the generation of possible EIAV variants in chronically EIAV 
infected horses.
TITRATION OF EQUINE INFECTIOUS ANEMIA VIRUS
The study of EIA was greatly hampered for a long period of time, as
the only way to demonstrate the etiological agent of the disease was by
74horse inoculation. Nevertheless, since 1955 Kobayashi et al. began
examining the possibility of propagation of EIAV in various tissue
cultures originated from the horse. They reported that of the tissue
cultures studied, bone marrow cell cultures and leukocyte cultures were
successfully used for the propagation and passage of EIAV. The same 
74authors also found that EIAV could be propagated in horse leukocyte 
culture, showing a sort of cytopathogenic effect (CPE), and that a 
strain of this virus which had been adapted to this type of cells could 
be assayed by using CPE as an indicator; however, they also pointed out 
that it took a long time to quantitate EIAV by using this type of cells, 
and that is was not always easy to keep horse leukocyte culture in a 
satisfactory state for a long period of time. After this report, many
other studies have been conducted about the growth characteristics of
EIAV in horse leukocyte culture^ including the changes in
78pathogenicity of EIAV through passages in these cells. Attempts were 
also made to grow EIAV in a variety of equine cell cultures and in cells
from animals of different species including chick embryo, Hela cells and
79 80BHK^ cells , as well as human fetal lung fibroblast. Furthermore,
avirulent strains of EIAV have been grown without the induction of CPE
in fetal equine kidney cells^5̂ ,  and in an equine dermal cell line
(ATCC-CCL 57).45
Equine infectious anemia virus has been titrated in horse
leukocyte culture^4,^  using CPE as an indicator, but as horse
leukocytes show spontaneous degeneration it is necessary to titrate the
virus by the second step or the third step passage method, which makes
the method difficult and tedious to perform. On the other hand, the
system is not satisfactory because it is very difficult to find a
suitable donor for the leukocytes, and an acceptable bovine serum to be
used in the culture medium.4  ̂ Amborski et al,^ described a simple
technique to titrate the infectivity of the cell-adapted strain of EIA
in the equine dermal cell line (ED) but the results are reported as
variable, therefore, the procedure is not completely satisfactory
either. Equine infectious anemia virus has been also quantitated in
vivo by injecting the infected material (blood, serum, plasma) into 
19susceptible horses ; but although simple and accurate, the procedure 
cannot be used on a routine basis because it is expensive and time 
consuming.
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The present study was conducted to (i) study the effect of serial 
passage on the virulence and in vitro growth of a cell adapted strain of 
EIAV; (ii) generate EIAV variant candidates for further characterization 
and biochemical comparison; and (iii) contribute to the development of 
immunoprophylactic protocols against EIAV infection.
MATERIALS AND METHODS
PONIES - Sixteen 2- to 4-year-old Shetland ponies negative for EIAV
antibody by the AGID test, were used to carry out the sequential passage
of the cell adapted strain, as shown in Table 1. The ponies were
stabled in separate stalls screened to exclude blood feeding insects.
The rectal temperature of each pony was recorded daily, and the AGID
test was performed on the recipient's serum collected three times/week,
until the first positive test was confirmed. In addition, nine more
ponies were used for the in vivo titration of plasma samples from ponies
No. 82, 91, and 64, collected at the first febrile episode after
inoculation; accordingly, ponies No. 12, 99, and 111 were recipients of
plasma from pony No. 82. No. 217, 112, and 122 from pony No. 91, and
ponies No. 94, 114, and 89 were recipients of plasma from pony No. 64.
Furthermore, two more ponies, No. 140 and 100, were intravenously (IV)
_2inoculated with 1 ml of a 10 dilution of plasma from pony No. 95, from 
which no virus was isolated after repeated attempts at cell culture. 
Finally, one more pony, No. 135, was IV inoculated with 250 mis of whole 
blood from pony No. 95 to demostrate the EIAV carrier status of the 
donor.
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VIRUS - The stock of equine cell-adapted strain of EIAV used in 
this study, was obtained from Dr. W. Malmquista in 1974, and 
subsequently passaged 109 times by Dr. C. J. Issel, Department of 
Veterinary Science, L.S.U. in equine dermal (ED) cells and stored at 
-80°C.
INOCULATION PROCEDURE - The procedure utilized to carry out the 
sequential passages of the cell-adapted strain of EIAV is depicted in 
Table 1. The table shows the donor(s), source, and infectivity of the 
inoculum material. The intravenous route was used in all cases.
After the ponies were inoculated, their rectal temperatures were 
recorded daily for at least 300 days. When a febrile response was 
detected (S39.2°C), 100 ml of heparinized blood was collected in 50 ml 
plastic tubes, the plasma separated by centrifugation at 1000 RPM for 10 
minutes, and stored at -80C° in 1 ml aliquots and in 50 ml glass tubes. 
The pony was then closely monitored for clinical signs of disease. 
Another blood sample was collected during afebrile periods, about 20 
days after the febrile attack for harvesting plasma and serum, for 
further virus isolation attempts, for comparative titrations, and for 
serum neutralization tests. Serum, and plasma were stored at -80C° 
until tested.
EVALUATING THE VIRULENCE OF EIAV ISOLATES - A grading scheme was 
used to evaluate the virulence of the EIAV "strains" generated by serial 
passage of the cell-adapted strain of EIAV in ponies, as follows. 
Numerical point values were assigned according to the number of days 
since the pony was inoculated and the initial febrile episode was 
observed, i.e., 5 points were given if £ 15 days, 4 points if 16 to 50
days, 3 points if 51 to 100 days, 2 points if 101 to 150 days, and 1 
point if 151 to 200 days. In addition, 0.5 point was given for each 
peak of fever occurring during the entire period of observation.
Similarly, 12 points were given if the pony died within 10 days of
illness, 8 points if between 11 to 20 days, 6 points if died between 21
to 30 days, 4 points if between 31 to 40, and 2 points if the course of
the disease was between 41 and 50 days. Besides, the time the animal 
lived after inoculation was also taken in account, and as a result 15 
points were assigned if the pony lived 20 days after inoculation, 12 
points if 21 to 50 days, 8 points if 51 to 100, 6 points if 101 to 150, 
and 2 points if 151 to 200. Finally, 0.5 point was given per each 
clinical sign exhibited during a febrile relapse. All observations of 
recipient ponies receiving DM treatments were not tallied in the 
virulence grading scheme.
DEXAMETHASONE ADMINISTRATION - The immunosuppressant dexamethasone 
(DM)^ was given to pony No. 47 (1st passage) on 200 PID to induce EIA 
disease as it had remained afebrile for the specified time, and to 
ponies No. 104 and 101 (2nd passage) which remained afebrile for 180 
days post-inoculation. In addition, pony No. 86 (2nd passage) was given 
DM at two separated occassions, one after the first febrile episode and 
a quiescent period of 151 days, and the second after its second febrile 
episode and an asymptomatic period of 228 days. Pony No. 96 (3rd 
passage) was also given DM at 405 PID, which was 165 days after its 4th 
febrile episode, to induce the recrudescence of EIA. Pony No. 95 (2nd 
passage) served as control (no DM). The DM dosage was 0.11 mg/kg of 
body weight daily for 5 consecutive days, by the intravenous route.
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IMMUNOSUPPRESSANT EFFECT OF DEXAMETHASONE - Ten mis of heparinized 
whole blood were collected from ponies No.86, 101, 104, and 95 (control) 
prior to the administration of the first dose of DM, on the day 
following the last dose, and finally, on the 10th day after the first DM 
injection was given. The total white blood cell count per microliter 
(yl), the total number of lymphocytes/yl, and the percentage of 
lymphocytes were determined by standard procedures. In addition,
clymphocytes were separated by the Histopaque-1077 procedure and counted
6 7according to a technique that is described elsewhere. The lymphocyte
subpopulations were also isolated (separation of T and B-lymphocytes) by
6 7“6 9nylon wool columns, according to standard procedures , and the
results were given as T and B-cells percentages.
Lymphocytes separated in the previous steps were subjected to
transformation by the technique described by Oppenheimer^ and modified 
68by Barta et al. The lymphocyte layers were treated with three
different mitogens at the following levels: (i) Phytohemagglutinin^
(100, 50, or 25 yg/well; (ii) Concanavalin A6 (100, 50, or yg/well; and
(iii) Pokeweed mitogen , 6 yg/well. After 4 to 5 days incubation,
tritiated thymidine^ was added at the doses of 5 yl/well (containing 1 
3microCi) H-thymidine solution in RPMI 1640. The cultures were 
reincubated for 18 hours at 37 C° in a humidified atmosphere containing 
5% CO2» The samples were then harvested with filter mats, which were 
then dried in the oven for 30 minutes at 60°C. Finally, the 
radioactivity was counted in a beta scintillation counter, allowing the 
vials to be counted for 5 minutes maximum. The results were given as a 
stimulation index (SI) which is obtained by dividing the counts per
25
minute (CPM) of stimulated cells by CPM of unstimu.lated cells from the 
same individual.
CLINICAL PATHOLOGY - Blood samples from 7 healthy, clinically 
normal 2 to 4 year old Shetland ponies, which were negative for antibody 
against EIAV in the AGID test, were analyzed to determine a normal mean 
value for hemoglobin concentration, packed cell volume (PCV), blood 
platelet count, and total white blood cell count (TWBC). The purpose 
was to have a base line for comparison with the same blood components 
from the chronically EIAV infected ponies involved in this study. 
Accordingly, samples of blood were obtained one day after some of the 
febrile recurrences from ponies No.82, 91, 90, 88, 64, and 117, for 
analysis of the aforementioned blood values. The analysis were carried 
out by standard procedures at the Clinical Pathology Laboratory, at the 
School of Veterinary Medicine, Louisiana State University.
POST-MORTEM EXAMINATION - A detailed necropsy was carried out for 
ponies No.47 (1st passage), 82 (2nd passage), 91, 90, 88, and 127 (3rd 
passages), 53 (4th passage), and 117 (6th passage), in cooperation with 
the Department of Veterinary Pathology, School of Veterinary Medicine, 
and the Louisiana Veterinary Medical Diagnostic Laboratory, Louisiana 
Department of Agriculture and the School of Veterinary Medicine, in 
Baton Rouge, Louisiana. Gross and microscopic lesions were recorded and 
related to clinic history and virus passage.
CELL CULTURES - Fetal equine kidney (FEK) cells prepared at the 
Department of Veterinary Science, LSU, were used as substrate to test 
for EIAV in plasma samples collected during and between sequential peaks 
of fever. The FEK cells were used in preference to ED cells because of
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marked increase in the production of EIAV cell-adapted strains in early
passaged FEK cells according to the author's previous findings. The
2cells were grown in plastic disposable tissue culture flasks (25 cm
growth area)®. A plasma volume of 0.5 ml was added to each duplicate
cell culture flask, which had been drained of media. One hour at 37°C
was allowed for viral adsorption. The monolayer was washed off twice
with phosphate-buffered saline solution (PBS) pH 7.4, and 5 ml of media
was added to refeed the cell monolayers. The cultures were incubated at
37°C for 2 weeks. The cultures were maintained with Eagles minimal 
ll cessential medium , 25 mM Hepes ; 10 mM sodium bicarbonate, (MEM) 
supplemented with 3% bovine fetal serum , plus 100 yg of streptomycin 
and 100 units of penicillin/ml. After two weeks incubation at 37°C, the 
culture fluids were harvested, clarified, and processed as previously 
described for EIAV antigen in the AGID test.^ Tests for antigen 
detection were repeated weekly for up to 12 weeks.
TITRATION OF VIRUS ISOLATES - Plasma samples from 38 selected 
febrile and afebrile periods were titrated in FEK cells to determine the 
amount of EIAV present. The results were expressed in terms of tissue 
culture infectious doses 50% of EIAV (log^) per 0.5 ml of plasma and 
are depicted in Figures 1 to 4.
The plasmas were diluted in ten-fold steps in MEM supplemented with 
10% bovine fetal s e ru m *1, then seeded on FEK cells in duplicate flasks in 
the amount of 0.5 ml/flask. The flasks were incubated for 60 minutes at 
37°C, the plasma excess was removed, the monolayer washed off with 5 mis 
of PBS, and the cultures refed with MEM containing 3% bovine fetal 
serum, and finally incubated at 37°C for 2 weeks. After this incubation
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the cultures were refed and the harvested supernatants were clarified, 
and the material processed by the ELISA technique, and by the AGID in 
some cases, to detect viral p26 antigen.
The ELISA technique, a modified double antibody sandwich 
tehchnique, was performed by Dr. Barbara Shane from the Department of 
Veterinary Science, L.S.U. The technique is briefly outlined as 
follows: (i) The wells of the plates1 were each coated with 100 ng of
horse IgG, which had been isolated and separated from the p26 reference 
antiserum by NH^CSO^) precipitation and sephacryl column 
chromatography. After coating, the plates were stored in the 
refrigerator for 40 hours. (ii) The wells were washed with PBS-Tween^ 3 
times and then 200 pi of test material (cell cultures supernatants) was 
added, followed by the addition of 5 pi of NP40 (a detergent). This 
step was followed by an incubation of 2 hours at 37°C. (iii) After the 
wells were washed 3 times with PBS-Tween 200 pi of a 1:2500 dilution of 
rabbit anti~p26 serum (antibody against EIAV p26 antigen produced in our 
laboratory) was added to each well followed by an incubation of 2 hours 
at 37°C. (iv) The wells were rinsed 3 times with PBS-Tween and goat 
anti rabbit alkaline phosphatase (antibody is prepared from goat anti 
rabbit IgG) diluted 1:1000 and in the amount of 200 pi was added, and 
the plates incubated at 37°C for 3 hours. (v) After this incubation, 
the wells were washed 3 times with PBS-Tween and the substrate 
(p-Nitrophenyl Phosphate, Disodium) 200 pg/well added, and the plates 
were incubated for 45 minutes at 37°C. (vi) Finally, the reaction was 
stopped with the addition of 50 pi of Na0H(2N), and the plates read in a 
photometer'*'. Adsorbance readings of 0.02 or less were found in
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uninfected tissue culture fluids, while readings of 0.1 or higher were 
regarded as positive for the presence of EIAV antigen (p26). Known 
dilutions of EIAV p26 as well as negative supernatants fluids and PBS, 
were included as controls.
IN VIVO TITRATION OF EIAV - The plasma samples collected during the
first peak of fever of ponies No. 82, 91, and 64 were titrated in vivo
-1 -3 -5as follows: one ml of the plasma dilutions 10 ,10 , and 10
respectively, was IV inoculated into susceptible ponies, according to
the following scheme: ponies No. 12, 99, and 111 recipients of pony No.
82; ponies No. 217, 112, and 122 recipients of pony No. 91; and ponies
No. 94, ll;t, and 89 recipients of pony No. 64. After inoculation the
rectal temperature of the ponies was recorded daily and 10 mis of whole
blood were collected every other day starting on the 5th PID, until the
animal became AGID test positive. The plasma infectivity was thus
estimated in this manner.
CROSS SERUM-NEUTRALIZATION - The cross serum-neutralization test 
was carried out by the virus dilution-constant serum method in
Ordisposable tissue culture flasks6. The stock material of each isolate 
was prepared as follows: plasma known to contain the virus isolate was
seeded onto FEK cells in ten-fold dilutions in duplicate flasks to 
determine infectivity titer. When the titration end point was stable, 
the supernatant from the end point was clarified and seeded onto fresh 
primary FEK cells in duplicate flasks for 4 to 5 days. Then the cells 
were split and reseeded in larger flasks™ (75 cm2 of growth area) and 
finally transferred to roller bottles™ (850 cm2 of growth area).
Finally, after EIAV antigen was detected in the supernatants by the
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ELISA technique, the supernatants of the cell cultures were clarified
and frozen in 1 ml aliquots, held at S 70°C and tested for EIAV
infectivity. The virus stocks used in the serum neutralization test had
an EIAV infectivity of to 10^ " TCID^q /0.5 ml. Sera to be tested
for antibody content were inactivated at 56°C for 30 minutes before
mixing with the virus dilution. The virus isolates were diluted in
—X “ 6ten-fold dilutions from 10 to 10 in cold MEM supplemented with 10%
FCS. Then, equal amounts of virus dilution and undiluted serum were
mixed and allowed to react for one hour at 37°C. After incubation, 0.5
ml of the mixture was inoculated onto FEK cells in duplicate flasks. As
controls, the virus dilutions were mixed and incubated with FCS, and
seeded onto FEK cells in duplicate flasks. Duplicate flasks of
uninfected FEK cells incubated with a negative horse serum (containing
no antibody against EIAV) were included. After the incubation period
each flask was rinsed with PBS to eliminate excess virus. The cells
were refed with fresh maintenance medium and kept at 37°C for two weeks.
After this incubation period the supernatant fluid from each flask was
harvested, clarified, and weekly tested by the AGID test to detect EIAV
66antigen according to the procedure described by Amborski at al.
Antigen prepared from the spleen of a horse with acute equine 
infectious anemia (007 of 06/21/76) and serum from a chronically 
infected mare (Lady) were used as reagents for the AGID test. Serum 
neutralizing activity was expressed as a log^g neutralizing index, 
calculated as the difference in l°g^Q of the titer of the virus samples 




FIRST PASSAGE - Two ponies (No. 47 and 80) were inoculated as the 
first virus passage (Table 2). Pony 80 was euthanized on 101 PID, 
because of progressive pneumonia after acute equine influenza. This 
pony became AGID test positive at 18 PID and did not show any clinical 
sign during the time it was under observation, other than fever and 
respiratory signs coincident with the equine influenza.
Pony No. 47 became AGID test positive on 20 PID and did not have any
febrile attacks for 200 days. The pony was then given DM; it developed
clinical signs compatible with EIA 41 days after the 5th (last) dose
(Figure 1). Clinical signs compatible with EIA included fever,
anorexia, drowsiness, pale mucous membranes, severe CNS depression,
diarrhea, weakness, and loss of weight (Table 3). This initial febrile
episode lasted for 10 days with 8 subsequent days with normal
temperature, followed by a second peak of fever with the aforementioned
clinical signs (Figure 1). The pony finally died after 16 days of
illness. Five virus isolates were derived from pony No. 47 (Table 4).
Two were isolated from samples collected before the pony became AGID
test positive. Each of these plasma samples had an infectivity of 10^*
TCID^q EIAV/0.5 ml plasma. One was isolated from each peak of fever
3.5(the infectivity of the plasma from the first peak of fever was 10 
TCID^q EIAV/0.5 ml plasma). The fifth virus isolate came from the 
plasma sample collected between the two peaks of fever.
SECOND PASSAGE - Five ponies were used for the second virus 
passage. Pony 82 became AGID test positive on 22 PID and showed the 
initial peak of fever on PID 106 (Table 2; Figure 2). Clinical signs
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compatible with EIA fever, anorexia, dullness, CNS depression, and 
profuse sweating were present for 2 days (Table 3). Subsequently this 
pony had 5 febrile attacks, but during the 2nd, 3rd, and 4th episodes no 
other clinical signs were observed. However, in the 5th and the 6th 
febrile episodes, there was severe disease requiring euthanasia at 358 
PID. Virus was isolated from 11 separate plasma preparations from pony 
No. 82 (Table 4). The plasmas collected at the peaks of fever had an 
infectivity of fe 10'*'*̂  TCID^q/0.5 ml, with the exception of the plasma 
from the fourth peak of fever which had an infectivity titer of 10^*^ 
TCID^q/0.5 ml. The highest plasma infectivity was 10^ " TCID^q /0.5 ml, 
while plasmas collected at afebrile stages had infectivity titers 
ranging between 10^* "* to 10^*^ TCID^q/0.5 ml.
Ponies No. 104 and 95 became AGID-test positive on 22 PID, and pony 
No. 101 on 24 PID, but in contrast to pony No. 82, none showed clinical 
signs of EIA through 180 PID. Ponies No. 101 and 104 were given DM at 
180 PID and pony No. 95 served as a control. Febrile episodes were 
noted after the second daily dose of DM had been given to pony No. 101 
and 5 days after the 5th dose in pony No. 104. Yet, clinical signs of 
other than the increase in rectal temperature were not observed (Table 
3). On the other hand, pony No. 95 remained afebrile (Table 5). One 
virus was isolated from plasma collected during the DM induced febrile 
relapse of pony No. 104, which had an infectivity titer of £ 10^*^
TCID^q EIAV/0.5 ml of plasma. The pony then experienced two febrile 
relapses from which two viruses were isolated. In addition, two viruses 
were isolated from afebrile stages (Table 4). No virus was isolated 
from pony No. 101, which experienced a second febrile attack 47 days 
after the first, accompanied by CNS depression and anorexia (Table 3).
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Pony No. 95, on the other hand, showed an increase in rectal temperature
on 235 PID, but no virus was isolated from the plasma collected at that
opportunity, and virus was not isolated from the plasma obtained 3 weeks
later. Therefore, two ponies (No. 100 and 140) were IV inoculated with 
-21 ml of a 10 dilution of the plasmas collected at the peak of fever, 
and at the afebrile stage following it. Neither of these two ponies 
experienced a febrile episode or became AGID test positive during 100 
PID. Consequently, pony No. 135 was IV inoculated with 250 ml of whole 
blood from pony No. 95. The recipient pony became AGID test positive on 
24 PID.
Pony 86 became AGID test positive on 25 PID and had fever initially 
on 133 PID. The second peak of fever appeared 41 days later, and the 
horse remained afebrile for the following 151 days (Figure 2). A 
short-lived febrile episode was observed with the 3rd dose of DM (Tables
2 and 5), but other signs of EIA were not observed. EIAV was isolated 
from each one of the three febrile episodes, but virus was, not isolated
J -
from plasmas collected after the 1st and the 2nd peaks of fever. A
virus was isolated from a sample collected at an afebrile stage
following the 3rd febrile relapse (Table 4). The plasma collected at
3 5the 1st febrile response had a titer of 10 ' TCID,_q EIAV/0.5 ml. In
addition, pony No. 86 was given a second DM treatment on 550 PID (228 
days after its last febrile episode, Table 5), but no clinical signs 
were observed within 30 days of treatment.
THIRD PASSAGE - The recipients of the 3rd virus passage became AGID 
test positive between 14 and 20 days after inoculation (Table 2). Pony
91 had six febrile episodes, the initial one appearing on 12 PID. Two
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more febrile attacks occurred within 60 days, but 138 days elapsed
between the 3rd and the 4th peaks of fever (Figure 3). Dullness, CNS
depression and anorexia accompanied the last three peaks of fever (Table
3), and at the same time certain hematologic changes were seen (Table
6). Virus was demonstrated and titrated from plasma collected during
all 6 febrile episodes and from 3 afebrile samplings (Figure 3). The
1st and the 2nd febrile episodes of pony No. 90 were followed by a rapid
sequence of febrile recurrences (Table 2; Figure 3) making it impossible
to collect the blood samples during defined afebrile periods. Fever was
the only clinical sign observed during the first three febrile
responses. In contrast, the 4th and the 5th febrile attacks were
accompanied by deep CNS depression, anemia, anorexia, loss of weight,
and diarrhea (which lasted for 10 days during the 4th episode). The
changes in hematological values of pony No. 90 are shown in Table 6, and
details about virus isolation are shown in Table 4. The infectivity of
3 5the plasma collected at the first febrile response was 10 ’ TCID^ 
EIAV/0.5 ml. Pony No. 88 suffered seven febrile attacks, the first one 
occurring on 14 PID, but 92 days elapsed between the first and the 
second febrile attacks. However, the following five febrile episodes 
occurred within 85 days, and caused a profound deterioration of the 
animal, which led to its euthanasia. The first three peaks of fever of 
pony No. 88 were not accompanied by EIA clinical signs, while the 
remainder were accompanied by CNS depression, anemia, anorexia, loss of 
weight, and weakness (Table 3). Details concerning febrile relapses are 
given in Figure 3, and details about virus isolation and hematological 
values from pony No. 88 are shown in Tables 3 and 6 respectively.
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Pony 96 also had a peak of fever on 13 PID, and then became AGID
test positive. Unlike the other third virus passages recipients, pony
No. 96 remained afebrile for 183 days after its first febrile episode,
which was followed by two more rectal temperature increases separated by
23 and 26 days respectively (Figure 3). No clinical signs accompanied
the first three peaks of fever, but the fourth was accompanied by CNS
depression, anorexia, anemia, and weakness (Table 3). Furthermore, pony
No. 96 was also given DM on 410 PID (165 days after the fourth peak of
fever), but no increase of rectal temperature or any other clinical sign
of EIA followed the DM treatment (Table 5). Finally, EIAV was isolated
3 5from plasma collected at the first peak of fever (10 ’ TCID,_q EIAV/0.5 
ml plasma), but virus was not isolated either from the samples collected 
at the other febrile relapses or from the material collected at afebrile 
stages. Details about duration of febrile episodes are shown in Table 2 
and Figure 3, clinical signs in Table 3, and virus isolation in Table 4.
Pony No. 120 had the first febrile attack on 12 PID and became AGID 
test positive two days later. Then two febrile relapses occurred within 
36 days and the pony died on 63 PID, after 16 days of clinical disease. 
The first two peaks of fever were accompanied by anorexia, CNS 
depression, and weakness, while the third febrile episode also included 
anemia and diarrhea (Table 3). The sequence of febrile relapses and the 
titer of EIAV in the plasma collected at the first febrile attack are 
shown in Figure 3. Pony No. 127 experienced the first febrile attack on 
13 PID and became AGID test positive on 17 PID. The pony suffered a 
total of 5 febrile episodes, the last one being fatal. The first 
febrile relapse was accompanied by CNS depression, anorexia, and
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weakness, while no signs of EIA were observed during the second febrile 
episode. The third and the fourth febrile attacks were accompanied by 
CNS depression, but appetite remained. During the fifth febrile 
episode, CNS depression, anemia, loss of weight, weakness, and diarrhea 
were present, but appetite remained until the last days of illness. The 
pony died after 15 days of clinical disease. Virus was demonstrated in 
8 samples from this pony, and all eight samples were titrated (Table 4; 
Figure 3).
FOURTH PASSAGE - The initial febrile episode was observed on 14 PID 
in pony No. 53. A second peak occurred 39 days later, and altogether 6 
febrile episodes were observed (Figure 4; Table 2). Clinical signs of 
EIA were not seen during the first through fifth febrile episodes, but 
the sixth episode was accompanied by anorexia, CNS depression, dullness, 
weakness, diarrhea, and edema of ventral body parts (Table 3). A total 
of 7 viruses were isolated from pony 53, and the plasma infectivity at 
the first febrile attack was found to be 10^’"* TCID^^ of EIAV/0.5 ml of 
plasma.
FIFTH PASSAGE - Pony No. 64 used as the fifth virus passage 
recipient showed the initial peak of fever at 14 PID. Six more peaks of 
fever occurred (Table 2), but only the fourth, fifth, and sixth febrile 
episodes were accompanied by CNS depression, anemia, anorexia, loss of 
weight, and weakness (Table 3). The adverse hematological changes after 
the second febrile episode gradually increased (Table 6). This pony 
died on 516 PID and had been under close observation during 300 days 
after inoculation. Details concerning the sequential febrile episodes 
are shown in Figure 4. Plasma collected at the first febrile episode
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4 5from pony No. 64 was titrated and found to have an infectivity of 10 
TCID^q of EIAV/0.5 ml of plasma.
SIXTH PASSAGE - Pony No. 117 served as the sixth virus passage, and 
had the first febrile relapse on PID 11 and then became AGID test 
positive on PID 18. The pony's temperature did not return to normal 
levels, and the horse died on 24 PID, after a clinical disease of 13 
days duration. The information concerning EIA clinical signs, virus 
isolation, virus titer, and hematological values are presented in Tables 
2 and 4, in Figure 4, and in Table 6, respectively.
In summary, the first passage recipient (pony No. 47) remained 
afebrile during 246 days after inoculation and when the animal came down 
with the disease it was striking and fatal, giving no opportunity for 
recovery of illness, whereas the second passage recipient ponies 
experienced the first febrile episode between 106 and 227 PID (two of 
them were DM induced) and experienced between one and six peaks of fever 
during at least 300 days period observation postinoculation. The ponies 
suffered an average of one febrile episode every 86 days. The third 
passage recipient ponies, on the other hand, suffered the first febrile 
attack at 12 or 13 PID (Table 2), and experienced from 3 to 7 febrile 
attacks during the time they were under observation. They had, on an 
average, a febrile attack every 36 days. Most of the third virus 
passage recipient ponies died before 200 PID, while all the ponies from 
the second passage lived for more than 300 days. The fourth passage 
recipient (pony No. 53) showed the first febrile attack on 14 PID, 
experienced 6 peaks of fever (one every 33 days, on the average), and 
died due to EIA after 8 days of severe illness. The fifth passage
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recipient (pony No. 64), also had the first febrile episode on 14 PID, 
experienced 7 febrile episodes during the 300 days period of 
observation, but died 516 PID. As previously mentioned, the fourth, 
fifth, and sixth febrile episodes of pony No. 64 were accompanied by 
severe clinical signs of EIA (Table 3), but the seventh (occurred on 235 
PID) was characterized by a rectal temperature increase only. On the 
contrary, the sixth passage recipient pony (No. 117) had the first 
febrile attack on 11 PID, and was continually sick .for 13 days, 
exhibiting all the clinical signs of EIA, except the ventral edema of 
body parts.
In Table 7, a classification is presented according to the type of 
EIA disease the inoculated ponies showed after inoculation and during 
the entire period of observation. Accordingly, pony No. 117 (sixth 
virus passage) suffered an acute form of the disease, while the first 
virus passage recipient (pony No. 47), one of the second passage 
recipient ponies (No. 82), five of the third virus passage recipients 
(Nos. 90, 91, 88, 120, and 127), as well as the fourth virus passage 
recipients (pony No. 53) and the fifth virus passage recipients (pony 
No. 64) suffered a type of disease characterized by its chronicity, with 
several and frequent febrile relapses, and a short episode of severe 
illness with fatal ending (subacute type). Only one of the ponies (No. 
96, a third virus passage) underwent a chronic form of the disease with 
frequent febrile relapses with no visible clinical signs of EIA, while 
four out of the 5 second passage ponies (No. 86, 104, 101, and 95) 
suffered a chronic form of the disease, with the occurrence of sporadic
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febrile relapses, but without observable manifestation of clinical EIA 
(inapparent).
The grading system utilized to evaluate the virulence of the virus 
strains generated by the serial passage of the ED cell-adapted strain in 
ponies was not applied to the observations of DM treated ponies 
following DM treatment in order to avoid a bias in the final results. 
Therefore, the results obtained were as follows: 0 points for the first
virus passage; 4.5 points for the virus second passage; 26 points for 
the third; 26.5 points for the fourth; 23 points for the fifth; and 28 
points for the sixth virus passage.
ISOLATION OF EIAV FROM FEBRILE AND AFEBRILE PERIODS - Equine 
infectious anemia virus isolates were made from 90% of the plasma 
preparations from material collected during a peak of fever, and from 
51% of plasmas collected at afebrile stages (either between two peaks of 
fever, after a peak of fever, or before the animal became AGID test 
positive). Equine infectious anemia virus antigen was first detected by 
the AGID test, at approximately the fifth week after seeding the plasmas 
onto FEK cells, the time varying from 2 to 11 weeks. There was no 
difference in the time required to detect the antigen from a sample 
collected at the peak of fever or at an afebrile stage, and 
CPE was not observed in the EIAV infected FEK cells.
EFFECT OF DEXAMETHASONE ADMINISTRATION - Pony No. 47 (first 
passage) was given DM on 200 PID as no clinical signs of EIA had 
occurred. There was no detectable clinical response that was 
temporally associated with this immunosuppressive treatment. In 
contrast, ponies No. 86, 104, and 101 (second passages) which were also
given DM, did have short lived febrile responses, but they were not 
accompanied by other clinical signs. Virus was demonstrated in plasmas 
from the DM induced febrile episodes from ponies No. 86 and 104, but not 
from plasma collected from pony No. 101. Pony No. 86 received a second 
treatment with DM on 550 PID and (228 days after the last febrile 
response), but with negative results. Finally, pony 96 (3rd passage) 
was given DM on 410 PID after suffering 4 febrile attacks 165 days after 
the last febrile episode, but with negative results (Table 5).
IMMUNOSUPPRESSANT EFFECT OF DEXAMETHASONE - Whole heparinized blood
was collected from ponies No. 86, 101, 104 and 95 (second passages) at
three occasions: before the first DM administration, on the day
following the last DM doses, and on day 10 after the first DM injection.
Total white blood cell counts (TWBC) and the percentage of lymphocytes
were determined for each one of the samples collected (Table 8). The
3results show that the TWBC was reduced by 3x10 /ul at the second count 
of pony 86, but the counts returned to about the initial value at the 
third count, while ponies No. 101 and 104 showed a slight increase in 
the TWBC in the second and the third counts (compared with the first 
count), and a similar result was found for pony No. 95 (control). As an 
average, the reduction of lymphocytes was of 20% and 25% at the second 
and third counts respectively, in the DM treated ponies, while in the 
control pony a reduction of 17% was found in the second count, but the 
third count was higher than the first. However, the response of the DM 
treated ponies was very variable as can be inferred from Table 8. 
Lymphocytes as a percentage were lower in the third count, compared to 
the first one in all the treated ponies.
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Lymphocytes of the same ponies were separated from the rest of the 
blood components, counted, and classified into T and B-cells, before DM 
administration, on the day following the last dose of DM, and on day 10 
after the first DM injection (Table 9). It was found that lymphocytes 
decreased by 52% in the second count of pony No. 86, but the count 
returned to pretreatment levels at the third count; while for pony No. 
104, the second count showed a decrease of 2.5%, and of 29.5% in the 
third count; however, lymphocytes of pony No. 101 were reduced by one 
third at both counts, compared with the pretreatment count. On the 
contrary, lymphocytes of the control pony were slightly increased at the 
second and third counts. T-cell counts on the other hand, were reduced 
by 17% in the second and third counts of ponies No. 86 and 101, while 
the decrease for pony No. 104 was negligible, and counts for control 
pony were equal to pretreatment counts. B-cells were reduced by 25% in 
the second count of ponies No. 86 and 104, but returned to pretreatment 
levels at the third counts, yet, for pony No. 104 B-cells were 
moderately reduced at the second count (4.3%), but decreased by 39.3% at 
the third count. B-cell counts of control pony remained substantially 
unchanged in the three counts.
The information concerning the results of the lymphocyte 
transformation test, carried out for lymphocytes from ponies No. 86,
101, 104 (DM treated) and pony No. 95 (control), are shown in Table 10 
(stimulation indexes). From these results, it seems that there was no 
effect of the DM treatment on the lymphocyte transformation 
(blastogenesis) in vitro, using the three mitogens we used at different 
doses, i.e., PHA, Con A, and Pokeweed mitogen. Finally, it seems that
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DM treatment did induce the occurrence of a febrile episode in ponies 
No. 86, 104, and 101, but not in ponies No. 47, 96, and 86 (in the 
second treatment).
In summary: (i) DM treatment causes a variable response in the
TWBC counts, but the general pattern would be a transient moderate 
increase, yet, lymphocytes as a percentage tend to decrease by about one 
third in general terms; (ii) T-cells were reduced by 17% compared to 
pretreatment counts; (iii) Reduction of B-cells were up to 39%; (iv) the 
DM treatment did not affect lymphocyte transformation assay Ln vitro 
with the mitogens used in this study; and (v) DM treatment did induce 
febrile episodes of EIA, in some chronically EIAV-infected ponies.
CLINICAL PATHOLOGY - Table 6 shows the hematological values 
obtained from 6 of the inoculated ponies, from samples taken one day 
after the beginning of the EIA febrile episodes. It is seen that 
hemoglobin is below normal values in all ponies after the febrile attack 
occurred and a steady tendency to decrease was found after each new 
febrile episode. Consequently, the same trend is found for the packed 
cell volume (PCV) for which values below 50% of normal are found after 
several febrile episodes. It seems that after the fifth or sixth 
febrile episode the PCV is under 20% (Table 5, ponies No. 91, 90, and 
88). On the other hand, excepting pony No. 117 (sixth passage) which 
suffered an acute illness, the blood platelet counts were found 
extremely diminished (50% of normal values in all the cases), sometimes 
as low as . 07xl0"Vpl (pony No. 90 after the fifth febrile episode). 
Similarly, the TWBC count was found to be below normal in most of the 
observations, tending to decrease even more with each new febrile
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3relapse, to reach values as low as 3x10 /pi, i.e., one-third of normal.
POSTMORTEM EXAMINATION. A detailed necropsy was carried out for 
ponies No. 117 (acute EIA - death following a short incubation period), 
No. 47 (first passage), No. 82 (second passage), Nos. 91, 88, 127, 120 
(third passage), and No. 53 (fourth passage), which suffered the 
subacute form of the disease (an initial febrile episode, followed by 
several febrile relapses and death after about two weeks of severe 
illness). The only chronic case of EIA was pony No. 96 (third passage) 
which was still alive at the time this work was written, while two of 
the horses suffering the inapparent type of EIA were euthanized, but no 
necropsy was performed.
The most prominent macroscopic and microscopic lesions were found 
in liver, kidney, spleen, lymph nodes, and bone marrow, while no 
prominent lesions were found in heart, colon, cerebrum and cerebellum, 
and no lesions attributable to EIAV were found in pancreas, small 
intestine, urinary bladder, thyroid, and pituitary gland.
In the acute case of EIA, liver was found to be enlarged, friable 
and swollen, and at the microscopic examination prominent fatty changes 
were seen, as well as large number of hemosiderin laden macrophages in 
the sinusoids, necrotic hepatocytes, and the periportal areas 
infiltrated by numerous lymphoid elements intermixed with few 
macrophages and neutrophils. In the subacute cases, the liver was found 
grossly normal in some cases, but it was usually congested, dark red 
with an accentuated lobular pattern, while the microscopic lesions were 
similar to those described for the acute case, with the exception that 
hemosiderocytes were much more abundant in the subacute cases. The
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kidney was macroscopically hemorrhagic in the acute case of EIA with 
very poorly defined striation in the cortex and medulla, while in the 
subacute cases, it was found pale or congested, and with petechial or 
ecchymotic hemorrhages. The microscopic lesions in both types of EIA 
were similar, mostly hemorrhages scattered through the parenchyma of 
cortex, vacuolar degeneration in the renal proximal tubular epithelium 
with dystrophic mineralization, the interstitium increased in prominence 
with lymphoid infiltration, and increase in neutrophils and macrophages; 
besides, the glomeruli were found to be hypercellular and tending to 
fill the Bowman's space, and also, a mild lymphocytic and plasma cell 
infiltration was found in the glomerular tuft. The spleen on the other 
hand, was found enlarged and dark red in the acute case, but in some of 
the subacute cases a normal size spleen was found, while the microscopic 
examination revealed a highly cellular spleen with splenic corpuscles 
larger than normal, germinal centers with many mitotic figures, and lack 
of maturation zones for the lymphocytes in the acute cases. In the 
subacute cases, lymphocyte infiltration and large areas of necrosis with 
fibrin and hemorrhages were the predominant lesions. Similarly, the 
lymph nodes were severely affected in both types of EIA disease, with 
hyperplasia and hemorrhages being the dominant macroscopic lesion, 
especially in the acute case, while the microscopic common lesion was 
hyperplasia with lymphocytic infiltration. The bone marrow showed 
evidence of regeneration of the hematopoietic tissue in the acute and in 
the subacute cases of the disease, and the microscopic findings were 
increased cellularity, large numbers of erythoblasts, prorubricytes, and
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metarubricytes, lymphoid and myeloid hyperplasia, abundance of plasma 
cells, and many macrophages with hemosiderin.
CROSS SERUM-NEUTRALIZATION TEST. The results of the cross serum- 
neutralization test carried out for 1 virus isolate with 3 antisera 
collected from pony No. 82 are shown in Table 11. The results show that 
virus isolate P82-1 (isolated 106 PID) was not neutralized by serum 
collected on PID 127, but was strongly neutralized by antiserums 
collected at a later stage of the disease (280 and 325 PID 
respectively).
The cross serum-neutralization test carried out for four virus 
isolates and three antiserums from pony 127 are presented in Table 12.
At first it is seen that the serum collected on 31 PID did not contain 
enough antibody to neutralize the virus isolate 127-1 and did not 
neutralize any of the other three viruses generated thereafter, while 
the serum collected at 125 PID did strongly neutralize the two virus 
isolates previously formed, but weakly neutralized virus isolate P127-3 
and failed to neutralize virus isolate P127-4. Finally, the serum 
collected on 158 PID did neutralize virus isolates P127-1, P127-2, and 
P127-3, but failed to neutralize virus isolate P127-4. From these 
results it can be seen that the neutralizing potency of a given serum 
sample varied when tested against different viruses. Serum collected at 
125 PID had the highest neutralizing indexes against virus isolates 
P127-1 and P127-2, and in a similar fashion, sera collected on 280 and 




Six serial passages of a cell-adapted strain of EIAV were carried 
out in a total of sixteen 2 to 4 year old Shetland ponies to study 
possible changes in virulence of this cell-adapted strain, and mainly to 
isolate EIAV from plasma samples taken at the time of febrile attacks, 
and also at afebrile stages of the infection. As a result, it was found 
that the virulence of this cell-adapted strain of EIAV increased through 
passages in ponies; in addition, a total of 77 isolates of EIAV were 
made, 55 from plasmas collected at the time of febrile episodes, and 22 
from plasmas collected at afebrile stages of the chronically EIAV 
infected ponies. It was found also that EIAV infectivity was higher for 
samples drawn at a febrile episode than for samples collected at 
afebrile stages. Furthermore, virus isolates and sera collected at 
different times after infection from the same pony proved the antigenic 
variation of the sequential virus isolates.
The sixteen ponies used for the successive passage of the cell
adapted strain of EIAV became AGID test positive between 14 and 25 PID,
13 18 19which is in agreement with previous reports. * ’ It was found that
the time required to detect precipitating antibody was approximately the 
same in the low and high virus passage ponies. The first febrile 
response occurred much earlier in the ponies receiving the highest virus 
passage (third, fourth, fifth, and sixth) than in the recipient ponies 
of the lower passages of the virus (first and second).
Pony 47, the first EIAV passage recipient had the first febrile 
episode on 246 PID; then, this pony had the longest incubation period, 
probably because it was inoculated with an EIAV attenuated through high
passage in cell culture; but despite this, the clinical disease the pony
underwent was one of the most severe observed in this study. On the
other hand, the response might be independent of the immunosuppressive
treatment, as DM induced immunosuppression would last for about one week
after the last injection (Table 9). The second passage ponies, on the
other hand, experienced the first febrile episode between 106 and 227
PID (two of them DM induced). The recipients of the third, fourth,
fifth, and sixth virus passages showed the first febrile attack between
11 and 14 PID, which would indicate an increase in the virulence of this
cell-adapted strain. The number of febrile episodes, the course of the
disease, the time lived after inoculation, and the EIA clinical signs
substantiate the statement that the virulence of the cell-adapted strain
of EIAV increases through serial passages in ponies, although individual
variation within passages was high. The second passage ponies scored
lower in the grading system, which might be due to the infection with an
EIAV which probably had not regained virulence, as compared with the
pattern of disease in the higher virus passages. The number of febrile
episodes experienced by the third passage ponies was similar to
18 19observations reported by Kono et al. ' , but do differ from another
_ 13 report.
Febrile episodes in most of the ponies lasted from 1 to 5 days,
11 17-19which is in accordance with previous reports. ’ . However, the
first passage recipient suffered two febrile attacks lasting for 10 and
16 days, respectively. The DM induced febrile episodes were short
lived. The clinical signs observed in this study are in agreement with
5 19reports from other workers. ’ Fever, CNS depression, anemia, loss of
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weight, and weakness were the most common EIAV clinical signs observed, 
while diarrhea was rarely seen, and only in terminal cases. Ventral 
edema was seen in one of the sick ponies only after about 30 days of 
continuous illness.
Equine infectious anemia virus was isolated from 90% of the plasma
preparations from blood collected at a peak of fever and from 51% of the
13 18plasmas collected at afebrile stages. In previous reports ’ , EIAV
was isolated in horse leukocyte cultures from serum samples collected at 
the same stages from chronically infected horses with production of CPE. 
Isolation of EIAV variants was accomplished at a high rate from plasma 
seeded in primary FEK cells, but without the induction of CPE. Since 
the isolation rates were similar for low and high passages, and from 
initial and final febrile episodes, it is suggested that the mutation of 
this cell-adapted strain of EIAV allows for its cultivation in FEK cells 
and is relatively stable.
No virus was isolated from pony No. 95 (2nd passage) or from pony 
101 (DM induced, second passage). To demonstrate the carrier status of 
pony No. 95, two ponies were inoculated with diluted plasma from that 
pony, but the two recipients remained EIAV susceptible; yet, the pony 
inoculated with 250 mis of whole blood from pony No. 95 seroconverted to 
positive in the AGID test on 27 PID. This result supports the concept 
that once a horse is infected with EIAV, it becomes an EIAV carrier for 
life."*’^ * ^  20,22,32 jjorses chronically infected with EIAV usually 
become quiescent and do not show EIA disease clinical signs for long 
periods of time, but they do have a persistent viremia, regardless of 
the clinical c o u r s e . ^  In this case the reasons for the failure
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to isolate EIAV from ponies No. 95 and 101 could be a lack of plasma 
viremia (EIAV present in leukocytes only); hence, the increase in rectal 
temperature was probably not due to EIAV replication and propagation in 
the host.
The EIAV variants generated through this study have been used in
several experiments concerning EIAV vector transmission. Accordingly, a
pony was IV inoculated with 1 ml of plasma prepared from whole blood
collected from the peak of fever of pony No. 53 (fourth passage), which 
3 5had a titer of 10 ’ TCID^^ of EIAV/0.5 ml of plasma. The recipient
pony showed clinical signs of the disease on 15 PID and 18 days later
showed neurological clinical signs which included CNS depression,
disorientation, knuckling at the fetlock, hypermetria, kneeling, rolling
on its back, and finally paralysis of the hind legs. These neurological
clinical signs do differ from those of visna virus affected sheep, as
the paralysis usually progresses slowly and the animal remains alert and
84can survive for several weeks. In addition, tremors of the head and
85facial muscles, and blindness are frequently seen. The cerebro spinal 
fluid was shown to contain antibody against EIAV, but no virus was 
isolated in primary FEK cells. EIAV was isolated from brain and spinal 
cord tissues and the material was found to have an infectivity of 10^'  ̂
TCID^q of EIAV/gm of tissue. The clinical description of this 
particular case is similar to a report from Mcllwaraith et al.^, but in 
this case EIAV was isolated and titrated from CNS tissue (the best 
source for visna virus isolation in sheep)Therefore, EIAV might 
play an important role in many clinical cases in which CNS clinical 
signs are observed.
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The infectivity titer of the plasmas from which EIAV was isolated
from a peak of fever varied from S 10^* TCID^q of EIAV/0.5 ml to 10'’"'*
2 5TCID^q of EIAV/0.5 ml of plasma, but usually the lowest titer was 10
TCID^q of EIAV/0.5 ml (a titer of 10^" "* TCID^q of EIAV/0.5 ml of plasma
was found in one case only). An increase in the EIAV plasma infectivity
was not found in sequential virus isolates from the same pony, the
18results being in agreement with a previous work. On the other hand,
the results of the in vivo and in vitro titrations were quite similar
suggesting that the quantitation of EIAV can be carried out in primary
FEK cells in an accurate manner, thus avoiding the use of other
cumbersome techniques.
According to the course of EIA disease the ponies suffered, most of
the cases corresponded to the subacute form characterized by the
occurrence of several febrile relapses and a fatal ending, which
5 11 17-19 32coincides with previous reports. ’ ’ * The acute form of the
disease seems to be infrequent, and in this case, only pony No. 117 
(sixth passage) was stricken by a highly passaged virus which had become 
very virulent, giving support to the notion that the cell-adapted strain 
of EIAV increases its virulence through successive passages in ponies. 
The inapparent form of the disease was more common than the chronic form 
and was shown by four of the five second passage recipient ponies, which 
might be an indication that relatively avirulent EIAV tends to be 
perpetuated in its host, being more stable than the virulent strains, 
and perhaps in a provirus state (integration of viral nucleic acid with 
the cell's DNA).
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The changes upon blood components indicated that the physical
condition of the ponies worsened with successive febrile attacks. The
blood platelet reduction was severe and coincident with the febrile
5 72attacks, which was consistent with previous reports. ’ The leukopenia
that usually increased with progressive febrile attacks might be related
to a suppressive effect of EIAV on the immune system of the host as
72reported for other retroviruses. The anemia observed in the ponies 
increased after each febrile attack, the hemoglobin and the PCV reaching
very low levels (a third of normal in some of the cases). This is in
„ . . 5,11,17,19,26-28,30-31,43agreement with previous reports.
The response of the chronically infected ponies to the
administration of the immunosuppressant DM was inconsistent and
unpredictable and was in partial agreement with results from Kono et̂
19 32al. ’ A short lived increase of rectal temperature was found in 3 of
6 ponies treated and EIAV was isolated from 2 of them, but no clinical
signs of EIA encompassed the induced febrile episodes. The TWBC
increased in 2 of the ponies treated (101 and 104), which is in
A 6agreement with some reports , but decreased in one of the ponies.
Thus, these results substantiate the statement that DM response is
A 6variable among DM treated ponies. Lymphocytes as a percentage were
consistently found low after DM treatment as previously 
19,47 49reported. ’ Separated lymphocytes and T-cells were found
decreased at the second count, but at about pretreatment levels at the
47 49third count, results that coincide with previous reports. Finally,
B-cells were reduced but in a lesser extent in general terms and no
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specific references on the effect of DM treatment on B-cells of
chronically EIAV infected ponies were found in the literature reviewed.
The cell-mediated immune system (CMI) is suppressed by repeated IV
administration of DM and latent viral infections may also be activated
46by corticosteroid administration . This is probably because
corticosteroids inhibit phagocytosis by macrophages by interfering with
antigen recognition, and altering immunologically induced inflammatory 
73reactions. It seems that sustained elevated plasma levels of
corticosteroids are necessary for suppression of various lymphocyte 
49functions and that there are differences in the corticosteroid
response among individuals of the same species. The cause of
lymphopenia induced by corticosteroids is not well known, but it has
48been found that DM induces irreversible arrest . Other reports 
suggest that the lymphopenia is due to a redistribution of lymphocytes 
from the circulation to other body compartments. Still other reports 
state that the lymphopenia is due to the destructive effect of 
corticosteroids on lymphoid tissue. It is possible that by inhibiting 
protein synthesis, corticosteroids suppress the afferent limb of the 
immune response.
The results of the lymphocyte transformation assay indicated that
there was no effect of DM treatment upon the lymphocyte blastogenesis, a
46result that does not agree with a report from Tarr et_ al. who found 
that DM in horses causes an average of 48% suppression of PHA induced 
blastogenesis, 43% suppression of Con A induced blastogenesis, and 29% 
suppression of PWM induced blastogenesis. Magnuson et al.^ reported 
that chronic in vivo treatment of ponies with corticosteroids caused a
marked decrease in the absolute number of circulating lymphocytes, but 
little effect on jin vitro PHA lymphocyte stimulation. Similarly, 
because peripheral blood lymphocytes from ponies appear not to be 
physically altered by large concentrations of corticosteroids and 
neither short nor chronic corticosteroid treatment affect the response 
of ponies to PHA, those authors suggested that the pony should be placed 
in the category of corticosteroid-resistant animals, along with man, 
guinea pig, and monkey. It is finally proposed that the apparent 
unaltered, mitogenic response found in this study is due to a decreased
4
number of suppressor T-lymphocytes in circulation.
The study concerning the macroscopic and microscopic lesions found 
in acute, subacute, and chronic cases of EIA showed that liver, kidney, 
and spleen of ponies which died due to acute EIA have marked gross and 
microscopic lesions of EIA, while in the subacute and inapparent cases 
those organs may not show macroscopic alterations or they are much less 
severe than the lesions found in acute cases. While microscopic lesions 
are severe and constant in the liver and kidney, the spleen may not 
exhibit prominent lesions. The lymphatic nodes are seriously affected 
in the three types of EIA, the most severe changes being found in the 
histopathological study of material from acute cases. The same 
macroscopic and microscopic lesions were found in the bone marrow of 
ponies dying due to either type of EIA disease. In addition, the 
lesions found in the heart of ponies dead by any type of EIA disease 
were found to be of no importance for the diagnosis of EIA. Macroscopic 
and microscopic lesions of the colon were found to be different in the 
acute, subacute, and inapparent types of EIA disease. No macroscopic
lesions of cerebrum and cerebelum were found in subacute and inapparent
cases of EIA while congestion was observed in acute cases; otherwise, no
microscopic lesions were found in cerebrum and cerebelum of acute cases,
but they were reported for chronic cases (slight infiltration of
lymphocytes in the meninges). These macroscopic and microscopic lesions
11 13are in agreement with previous reports. ’
As previously mentioned, a pony for another project was inoculated
with a virus isolate generated in this study and developed clinical
signs of neurological disease already described and consistent with
meningoencephalitis. The macroscopic and microscopic lesions comprised
enlargement of the ventricular system, and grey-brown discoloration of
ventricular surfaces, but no lesions were found in the spinal cord. The
histological lesions observed in the brain were mostly meningitis,
choroiditis, granulomatous ependymitis, subependymal encephalitis, and
lymphoid infiltration into the subependymal neuropil and a lesser number
of reticuloendothelial cells. These macroscopic and microscopic lesions,
as well as the clinical signs are in agreement with a previous report
71from Mcllwaraith et al. and occurred in an acute case of EIA. These
macroscopic and microscopic lesions are also found in sheep dead due to
visna virus infection, but demyelination is a prominent effect in the
84brain of visna virus affected sheep. In addition, visna virus 
produces lesions in the spinal cord. These lesions, on becoming
confluent, give rise to large lesions which tend to necrose and form
86 87cavitations. As pointed out by McClure et al. , there is possible a
number of cases in horses showing progressive hind-end incoordination
due to EIAV damage within the spinal cord. In this case, the clinical
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signs point to the brain and are correlated with the macroscopic and
microscopic findings in the altered brain structure and tissue.
The results of the cross serum-neutralization test carried out for
virus isolate P82-1 (isolated from plasma taken at the first febrile
episode of pony No. 82) and 3 antisera collected at different times
after inoculation, and for 4 virus isolates and 3 antisera from pony
127, showed that the virus isolates from the same pony are not
neutralized by sera collected before their isolation. Sera collected at
about 30 days after a febrile episode, however, show neutralizing
activity which increases in subsequently collected serum samples. These
13 18 19results are in agreement with previous reports. * *
The fact that a serum collected after a febrile episode neutralizes
EIAV previously generated is something expected, as antibody previously
formed against previously arisen EIAV strains would be present in the
serum; then, as found in this study, a serum collected at a defined time
after inoculation, does not contain antibody against EIAV appearing
after the serum collection. This result would indicate a partial common
antigenicity between the virus isolated one after another in the same
pony, but at the same time would indicate an antigenic variation (a
subtle change) in the EIAV isolate.
Finally, if the EIAV variants are formed, either under the pressure
28of the host immune response (antibody and Tk cells mostly) , or by 
natural mutation (not induced by external stimulus), in both cases by 
accumulation of point mutations (that involve a single nucleotide), the 
host cell mediated immune response would contribute to the propagation
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of the new virus variants, as the virus hides in the leukocytes (mostly 
macrophages) to escape the host immune system.
A work from Parekh jit al. showed that EIAV contains four major 
nonglycosylated proteins (p26, pl5, pll, and p9) and two glycoproteins 
(gp90 and gp45), which together account for greater than 95% of the 
total virion protein. As the nature of the antigenic variation of EIAV 
has remained unknown, Parekh et̂  al. undertook the biochemical analysis 
of virus isolates P82-1 and P82-6 which were obtained in this work, from 
plasma samples collected at the first and sixth episode of pony No. 82, 
a virus second passage. The SDS-PAGE revealed different electrophoretic 
mobilities for the respective virion surface glycoproteins (gp90 and 
gp45) , but identical migration rates for the internal nonglycosylated 
virion proteins (p26, pl5, pll, and p9). Peptide mapping comparisons 
demonstrated structural variations between gp90 and gp45 components of 
the P82-1, P82-6, and the prototype cell-adapted EIAV strain, but the 
identity of the virus variants was maintained in long term culture of 
the viruses in FEK cells. It was also found that structural alterations 
seems to be much greater in gp45 compared to gp90, but, in contrast to 
the glycoproteins of EIAV, no differences were detected among the major 
nonglycosylated virion proteins p26, pl5, pll, and p9, when they were 
compared by the same procedures. The suggestion is that during 
replication in the horse, EIAV glycoproteins can undergo detectable 
structural alterations in the absence of any change in the major 
internal proteins of the virus. Changes in glycosylated or 
nonglycosylated proteins were not detected during replication in vitro 
where immune pressure was absent. The nature of the antigenic variation
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in EIAV remains to be determined and it is unknown whether the observed 
structural alterations occur in amino acid sequence, oligosaccharide 
structures, or both. Analysis of the glycopeptide fractions by gel 
filtration procedures may elucidate further, the site(s) of antigenic 
variation in EIAV. The identification of key antigenic determinants in 
the glycoproteins of EIAV, and the effects of changes in these regions 
on serological properties may provide the information necessary for 
developing effective immunization regimes against EIA disease. Through 
this study, the required reagents have been collected and prepared to 
continue the effort to elucidate the case of the antigenic drift in 
EIAV, and hopefully to obtain an effective vaccine against EIA virus.
SUMMARY
Six serial passages of a cell-adapted strain of EIAV were conducted 
in Shetland ponies. The 16 recipient ponies became agar-gel 
immunodiffusion positive by 25 days post-inoculation. The first virus 
passage recipient had the first febrile response on 246 post-inoculation 
day (PID), while ponies from the second passage showed the first febrile 
attack after 100 PID, and some of the febrile responses were 
dexamethasone induced. On the other hand, ponies from the third through 
the sixth passage experienced the first febrile response by 13 PID.
The most important clinical signs exhibited by the ponies, along 
with the EIA episodes were fever, CNS depression, anemia, anorexia, loss 
of weight and weakness, while diarrhea and ventral edema of the body 
parts were rarely observed. The subacute type of the disease was 
predominant, followed by the inapparent type, and only the highest 
passage pony suffered the acute type of the disease. In addition,
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according to the results of a grading scheme prepared to evaluate the 
virulence of the virus isolates, it was found that the virulence of the 
cell-adapted strain increased through serial passages in ponies, 
although individual variations occurred.
Changes upon the blood components were studied from samples taken 
on the day following some of the febrile attacks, and as a result, 
hemoglobin, the packed-cell volume, the total count of leukocytes, and 
the thrombocytes were found under normal levels; in addition, the 
immunosuppressant dexamethasone (DM) was given to some of the ponies to 
induce clinical signs of EIA and to study its effect upon white blood 
cells. It was found that DM induced a short-lived febrile response in 
three of the five treated ponies, but EIAV was isolated from plasma of 
two of the ponies only. Besides, it was found that DM treatment induces 
a transient increase in total white blood cell counts, while T and B 
cell counts were reduced. In addition, the DM treatment did not affect 
the lymphocyte transformation in vitro with the mitogens used in this 
study.
Postmortem examination conducted in ponies which died due to acute 
and subacute types of EIA, showed that severe hemorrhagic lesions were 
common in the acute cases, and that the most affected organs in both 
types of EIA disease were liver, spleen, kidney, lymph nodes, and bone 
marrow, as derived from the microscopic examination of the affected 
tissues.
Equine infectious anemia virus was isolated from 90% of the plasmas 
collected at febrile stages and from 51% of the plasmas collected at 
afebrile stages. The plasmas were seeded on primary fetal equine cells,
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where EIAV grew without the induction of cytopathogenic effect. In 
addition, the EIAV plasma infectivity was found to be higher for plasma 
samples collected at the peaks of fever, than from plasmas collected at 
afebrile stages. Finally, the cross serum neutralization test was 
carried for one virus isolate from a second passage pony, and for four 
virus isolates from a third passage pony, with sera collected from the 
same pony at different times after inoculation. It was found that serum 
collected a short period of time after virus isolation, did not have any 
neutralizing activity against the virus isolate, but the neutralizing
4
activity increased in sera collected thereafter. Equally important, a 
serum collected at a given time displays neutralizing activity against 
isolates made previously, but not against cloned isolates of EIAV from 
febrile episodes after the serum collection. This finding supports the 
suggestion that antigenic variation of EIAV occurs within the horse, and 
may be the mechanism by which the virus temporarily escapes the host 
immune response. The mechanism known as "antigenic drift" of EIAV, has 
hampered the production of an effective vaccine against EIA, and also 
the establishment of an operative sanitary campaign. It is possible 
that by the future research on EIA at Louisiana State University, using 
the reagents generated through this study, the nature of the antigenic 
variation of EIAV will be disclosed, making possible the production of 
an immunogen against equine infectious anemia disease.
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n. The EIAV isolates are named according to the pony from which the
virus was isolated, and the respective febrile relapse; for 
instance, P82-1 is the EIAV isolate from the first peak of fever of 
pony 82.
o. Glycoprotein changes associated with antigenic variation during
persistent infection by equine infectious anemia virus, a 
retrovirus. Sent for publication on 01/26/83 to J Biol Chem.
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TABLE 1. Inoculation procedure utilized to carry out the sequential passage of cell-adapted strain of 
EIAV in sixteen Shetland ponies
Donor Source of




















Pool of plasmas collected 
before first AGID positive 
test (18 and 16 respectively)
Plasma collected before first 
AGID positive test (18)
Plasma collected at first 
febrile episode (106)
Plasma collected at first 
febrile episode (12)
Plasma collected at first 
febrile episode (14)





































1st cell culture 47 291 20 246(1)* 275(16) Died on 291 !PID
f  80 101 18 (Euthanized on PID 101)
( 82 358 22 106(2) 135(2) 195(3) 214(20) 264(3) 302(3)
/ponies 47 and 80 < 104 300 22 187+(1) 210(2) 243(3)
2nd « (pooled plasma) 1 95 300 22 227(3)) V^ioi 300 24 181+(2) 228(2)
I Pony 47 plasma -  86 580 25 133(3) 174(3) 325+(l)
C 91 323 19 12(2) 32(2) 58(2) 198(5) 228(7) 280(6)\  90 157 20 13(2) 96(2) 118(4) 137(10) 152(10)
3rd Pony 82 plasma 1 88 211 20 13(2) 105(2) 115(2) 128(4) 153(5) 165(3) 190(2)
1 96 440 18 13(1) 186(3) 216(2) 245(3)I 120 63 14 12(5) 35(5) 47(16)
(  127 172 17 13(12) 41(2) 99(2) 137(2) 158(15)
4th - Pony 91 plasma 53 211 20 14(2) 53(3) 132 ('2) 167(7) 182(7) 199(8)
5th - Pony 53 plasma 64 300 20 14(5) 23(2) 28(1) 37(1) 91(4) 167(11) 235(2)
6th - Pony 64 plasma 117 25 18 11(14)
* 0 * Duration of febrile episode in days. 
Dexamethasone associated febrile episode.

















1st 47 1,2 X X X X X X X
2nd 82 1 X X X
2-4 X
5 X X X X X X
6 X X X X X X X
86 1-3 X
104 1-3 X
101 1 X •
2 X X X
95 1 X X X
3rd 91 1-3 X
4-6 X X X X
90 1-3 X
4,5 X X X X X X X
88 1-3 X
4-7 X X X X X X
96 1-3 X
4 X X X X X
120 1.2 X X X X
3 X X X X X X
127 1 X X X X
2 X
3,4 X X
5 X X X X X X
4th 53 1-5 X
6 X X X X X X X X
5th 64 1-3 X
4-6 X X X X X X
7 X **
6th 117 1 X X X X X X X
TABLE 4. Reisolation success of a cell-adapted strain of EIAV in fetal equine kidney cell cultures from 








Isolation success/isolation attempts 
' Febrile Afebrile No. of isolates
1st 47 2 2/2 3/3 5
2nd 82 6 6/6 5/6 11
86 3 3/3 1/3 4
104 3 3/3 2/3 5
95 1 0/1 0/1 0
101 2 0/2 0/2 0
3rd 91 6 6/6 3/6 9
90 5 5/5 0/2 5
88 7 7/7 0/1 7
96 4 1/4 1/4 2
120 3 3/3 1/2 4
127 5 5/5 3/4 8
4th 53 6 6/6 1/3 7
5 th 64 7 7/7 2/3 9
























47 1st 200 0 0 negative
86 2nd 319 2 151 fever 1
104 2nd 180 0 0 fever 1
101 2nd 180 0 0 fever 2
*86 2nd 550 3 228 negative
96 3rd 410 4 165 negative
(Control 95) 2nd 180 0 0 negative
2nd dexamethasone treatment.





Serial no. of 
febrile episodes Hemoglobin (g/dl) PCV (%)
Blood platelets 
(x 10 /ul) WBC (x 103/ul)
2nd 82 6th 11.7 31 0.52 11.6
3rd 91 4th 14.4 37 0.90 10.7
5 th 12.0 33 1.16 10.8
6th 7.4 19 0.54 4.2
3rd 90 2nd 8.9 22 0.95 10.7
3rd 8.4 23 0.98 6.7
4th 8.9 24 0.80 9.0
5th 5.7 15 0.07 3.0
3rd 88 5th 6.5 18 1.40 7.4
6th 5.9 17 1.40 10.9
5th 64 2nd 13.8 36 0.44 5.1
3rd 11.4 29 *N.D. 6.8
4th 10.7 28 0.82 8.4
6th 117 1st 10.2 28 3.4 7.1
Mean values in clinically 
healthy ponies (n = 7 ponies) 13.4 to 16 38.5 to 42 2.6 to 3.3 8.0 to 13.6
N.D. = not done.
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TABLE 7. Type of EIA disease suffered by 16 Shetland ponies subjected 
to successive passage of cell-adapted strain of EIAV
Type of Pony No.
EIA Disease Clinical characterization and backpassage
1. Acute short incubation period, 
severe clinical signs, 
short course
117(6th)
2. Subacute several febrile relapses, 





3. Chronic frequent febrile relapses, 96(3rd)
no apparent EIA clinical signs
4. Inapparent sporadic febrile relapses, 
no apparent EIA clinical signs
86,104,101,95
(2nd)
TABLE 8. Effect of dexamethasone treatment on total white blood cell and lymphocyte counts in 3 ponies
chronically infected with EIA virus (86, 101, and 104)
kPre-treatment *Second count "kThird count
Pony no. **WBC **Lymphocytes %+ WBC Lymphocytes % WBC Lymphocytes %
86 10.4 4.1 39 7.4 2.4 33 9.9 3.4 34
101 9.0 5.5 61 9.6 4.2 44 10.7 3.5 33
104.
955
10.9 6.6 61 11.5 6.9 60 11.5 3.2 28
10.7 6.1 57 12.2 5.1 42 11.8 6.6 56
X 10.2 5.0 54.5 10.2 4.6 44.8 11.0 4.2 37.8
SD 0.85 1.6 10.5 2.1 1.9 11.2 0.85 1.6 12.4
Normal
values 5.5 - 12.5 2.5 - 7.5 55.0




TABLE 9. Effect of dexamethasone administration on lymphocyte and T and B-cell counts in ponies chronically 
infected with EIAV
Pony no.
Lymphocytes (after separation)* T--cells (%) B--cells (%)
**Pre-treat **2nd **3rd Pre-treat 2nd 3rd Pre-treat 2nd 3rd
86 10 4.8 10.2 71.0 58.7 62.4 16 12.6 17.5
101 8.0 5.3 6.7 74.3 61.7 72.3 14 10.1 14.5
104 8.5 8.3 6.0 72.0 70.2 72.0 16 15.3 9.7
95 7.3 10 10.3 73.0 72.0 75.0 15 15.4 20.1
X 8.45 7.1 8.3 72.5 65.6 70.4 15.2 13.3 15.4
SD 1.1 2.5 2.3 1.4 6.4 5.5 0.9 2.5 4.5
* 3 /x 10 /pi of whole blood.




TABLE 10. Stimulation index of lymphocytes from ponies 101, 104, and 86, which were chronically 
infected with EIAV and treated with the immunosuppressant dexamethasone
Mitogen ADose
Pony number
101 104 86 AA95
SI1+ SI2 SI3 SI1 SI2 SI3 SI1 SI2 SI3 SI1 SI2 SI3
PHA 100 87 29 113 65 33 64 14 8 5 69 6 163
50 53 37 97 46 35 49 12 13 5 58 12 90
25 26 30 47 20 13 24 5 14 2 30 10 27
Con A 100 44 51 49 19 31 31 16 23 5 19 24 49
50 10 17 15 4 2 4 2 5 2 4 7 6
10 1 1 2 1 1 1 1 0 1 1 1 1
PWM 6 30 56 50 32 51 33 21 27 16 11 25 95
*Micrograms.
aaControl.
+Samples collected prior to (SI^), 5 (S^), and 10 (SI^) days after first injection.
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TABLE 11. Serum neutralization indexes of three sera collected from pony 
No. 82 at different times after isolation of virus P82-1 
(first peak of fever).
______Serum collected on PID______
Virus isolate Day PI 127 280 325
ArtP82-1 106 1.0 4.0 4.0
Post-inoculation day.
L°gio Serum-neutralization index (positive if k 2.0).
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TABLE 12. Serum-neutralization indexes of three sera collected from pony 
127 at different times after inoculation. Each serum was 
reacted with four sequential virus isolates from the same 
pony.
______Serum collected on PID______
Virus isolate Day PI 31 125 158
P127-1 13 1.5 3.0 3.0
P127-2 41 0.5 3.0 2.5
P12/-3 99 1.5 2.0 2.5
P127-4 137 1.0 1.0 1.0
Post-inoculation day.
Log^g serum-neutralization index (positive if S 2.0).
FIGURE 1
DAYS POST INOCULATION
FIGURE 1. Daily rectal temperature (C) of ponies 47 and 80 after IV inoculation of 10 TCID /ml of 
an equine dermal cell adapted strain of EIAV. V = EIAV isolated from plasma samples cultured in FEK 
cells. + = first AGID test positive. Bars = indicate the plasma infectivity (log TCID n/.5 ml). 
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DAYS POST INOCULATION
FIGURE 2. Daily rectal temperature (C) of ponies utilized as the second passage for the equine 
dermal-cell adapted strain of EIAV. V = EIAV isolated from plasma samples cultured in FEK cells.
V = EIAV was not isolated. + = first AGID test positive. The bars indicate the plasma infectivity 
(log TCID^q of EIAV/0.5 ml). DM = dexamethasone administration, first dose of a series of five 
injections.
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DAYS POST INOCULATION
FIGURE 3. Daily rectal temperature (C) of ponies used as the third passage of a cell-adapted strain 
of EIAV. V = EIAV isolated from plasma samples cultured in FEK cells. V = EIAV was not isolated.
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FIGURE 4. Daily rectal temperature (C) of ponies utilized as the fourth, fifth, and sixth passage of 
a cell-adapted strain of EIAV. V = EIAV was isolated from plasma samples cultured in FEK cells.^
V = EIAV was not isolated. + = first AGID test positive. The bars indicate the plasma infectivity 
(log1Q TCID50 of EIAV/0.5 ml).
CHAPTER II 
Equine Infectious Anemia:
Attempts to Titrate the Virus by Three Different Methods
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INTRODUCTION
Equine infectious anemia (EIA) is an infectious disease of
solipeds, also known as "swamp fever" as the disease occurs in animals
raised in low lying areas.* The etiological agent of EIA is a virus
from the Family Retroviridae which resembles visna, maedi, and
progressive pneumonia viruses. The virus is spherical, enveloped, and
the virion has a diameter of 80 to 100 nm. The icosahedral capsid
contains a heavy molecular weight RNA genome (60 to 70 S) composed of 
2subunits. The virus density is between 1.16 and 1.18 g/cm3 in sucrose 
3gradients , and like prototype retroviruses matures by budding from
cytoplasmic membranes.
Horse leukocyte culture was the first cell system successfully used
£
for the propagation and passage of EIAV , and also for its titration as
the virus produces a sort of cytopathogenic effect (CPE). In addition,
virulent strains of EIAV have been grown without the induction of CPE in
7 8fetal equine kidney (FEK) cells ’ , and in an equine dermal cell line 
9(ATCC-CCL) . Likewise, EIAV has been grown in cells from animals of
different species, including chick embryo, Hela cells, BHK^ cells^, as
well as human fetal lung fibroblasts^.
Different systems have been utilized to titrate EIAV, but no one is
easy and accurate. In fact, as already mentioned, EIAV has been
11 12titrated in horse leukocyte culture using CPE as an indicator ’ , but
as horse leukocytes show spontaneous degeneration it is necessary to 
titrate the virus by the second or the third step passage method, which 
makes the work difficult and tedious to perform; in addition, the system 
is not satisfactory because it is very hard to find a suitable donor for
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the leukocytes, and an acceptable bovine serum to be used in the culture 
9medium. A simpler technique to titrate the cell adapted strain of EIA
13virus in the equine dermal (ED) cell line has been described , but the
results are reported as variable; therefore, the procedure is not
completely satisfactory either. Likewise, EIA virus has been titrated 
14in vivo , by injecting the infected material (blood, serum, plasma) 
into susceptible horses. This procedure although accurate and simple is 
time consuming and costly, which reduce its usefulness for EIA virus 
quantitation.
Murine leukemia viruses replicate in tissue culture, but do not
produce CPE; consequently, serologic or bioassay methods have been
required to assay their growth, and plaque type assays had not been
feasible until 1970 when an indirect method of producing CPE was 
15 16described. ' The method so called "mixed culture cytopathogenicity 
reaction,"'*’"’ is based in the occurrence of syncytium formation when the 
XC cell line , a rat tumor cell originally induced by the Prague strain 
of Rous sarcoma virus is placed in contact with cells infected with 
murine leukemia virus; accordingly, murine leukemia virus is seeded in 
mouse embryo cultures from 15 to 17 day old NIH Swiss and BALB/c, and on 
the 5th or 6th day after infection the culture fluid is removed, and the 
cells are exposed for 20 to 30 seconds to ultraviolet (UV) irradiation 
from two GE germicidal bulbs located at 27.6 cms (60 erg/mm2/sec). 
Maintenance medium containing 10^ XC cells is then added, the fluid is 
changed at 1 or 2 day intervals, the cultures are fixed with methanol 
and stained with hematoxylin on the 3rd or 4th day after the addition of 
the XC cells, and plaques are read under low magnification of a
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dissecting microscope. The UV treated cultures show CPE represented by 
rounding and detachment of the mouse embryo cells; while the XC cells 
grow into a uniform monolayer. The plaques are seen as holes in the 
cell sheet which form as XC cells form syncytia over the infected mouse 
cells.
The procedure described has been used to quantitate several 
laboratory strains of murine leukemia virus (Gross, Moloney, Friend, 
Rauscher, WM-l-B, Graffi, Kirsten, and Kaplan), all tissue culture 
isolates of field strains tested, and naturally occurring virus in 
tissues of AKR, BALB/c, C„H/Bi, and C mice.^ Besides, the technique
J JO
has been used to titrate replication-defective ecotropic murine leukemia 
viruses, by a procedure known as "helper dependent XC plaque 
formation."^
The syncytia infectivity assay (SIA) has been used to titrate 
bovine leukemia virus, as it is capable of inducing rapid syncytia
formation in monolayer cell cultures of nontransformed cells from
18_20 20 21 various species. In this assay bovine embryonic spleen cells * ,
22as well as F-81 cells , have been used as indicators, and the monolayer
is treated with diethylamino-ethyl-dextran (DEAE-d) prior to virus
inoculation; then after a 48 hour incubation, the monolayer is fixed and
stained, and the results are given in syncytia forming units (SFU).
The inhibition of viral replication by the presence of other
viruses (interference) has been used to titrate some non-cytopathogenic
viruses; for instance, hog cholera and Sindbis viruses (Togaviridae)
induce a transient refractory state to vesicular stomatitis virus 
23(Rhabdoviridae). This type of interference is known as heterologus
24 24 25viral interference. Laude , and Fukusho at al. , report the reverse
plaque formation (RPF) by hog cholera virus inducing interference with
vesicular stomatitis virus (VSV), and how this phenomenon is used as a
rapid and simple procedure to quantitate several strains of hog cholera
virus (HCV). In this procedure, they grew the swine kidney cell line
25SK-H, and swine testicle (ST) cells , and when the monolayer was 
confluent they inoculated HCV; then, after viral adsorption the 
monolayer was covered with a 3% methylcellulose solution, and after 2 
days of incubation at 37°C, the methylcellulose was removed and the 
monolayer infected with VSV at a multiplicity of infection of about 2 
plaque forming units/cell; finally, after an incubation of 15 to 20 
hours at 37°C, the plates were stained and the reverse plaques 
visualized and counted. The plaques were produced as colonies of HCV 
infected cells which were refractory to VSV infection, standing out in 
the background of a VSV-sensitive, disintegrated cell sheet. Incubation 
for 3 and 4 days gave plaques ranging from 1 to 3 mm, and from 2 to 5 mm 
in diameter respectively. Cells in a circular plaque were all intact 
and surrounded by disintegrated cell debris; equally important, reverse 
plaques could be also developed on replicated dishes under a liquid 
medium without methylcellulose overlay medium.
The objectives of this study was to determine whether EIAV can be 
titrated by the mixed culture cytopathogenicity reaction, the 
syncytia-infectivity assay, and/or the reverse plaque assay.
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MATERIALS AND METHODS
THE MIXED CULTURE CYTOPATHOGENICITY ASSAY
Virus - The equine infectious anemia virus used in all the trials
was an EIAV stock N°376 (Wyoming strain), with a titer of 10"5’"5 TCID^q
of EIAV/0.5 ml, obtained from Dr. C.J. Issel, Department of Veterinary
Science, Louisiana State University.
Cell Cultures and Mediums - FEK cells prepared at our Department
were used as substrate to grow EIA virus. The cells (1 X 10'’) per well
were grown in multi-well plates with 6 flat bottom wells, with 9.6 cm2 
£
approximately (growth area). The cultures were fed with Eagles minimal
b cessential medium with 25 mM Hepes , 100 micrograms of streptomycin and
100 U of penicillin/ml (MEM), supplemented with 10% bovine fetal serum^.
9XC Cells - (ATCC CCL 165) are a certified cell line derived in 
1961 by D. Simkovic et al. from a transplantable tumor developed by J. 
Svoboda in 1960. The tumor was induced in newborn white-Weston rats by 
the intramuscular injection of the Prague strain of Rous sarcoma virus. 
The XC cells used to conduct this research were obtained in the passage 
109, from Dr. G. Amborski from the Cell and Organ Culture Laboratory, at 
the School of Veterinary Medicine, Louisiana State University. The
■Ĵ
cells were maintained at 37°C and refed every other day with MEM 
additioned of 3% bovine fetal serum'5.
Ultraviolet Irradiation - Equine infectious anemia virus infected 
and noninfected FEK cells were exposed to UV irradiation for 30, 60 90, 
120, 150, and 180 seconds, from a germicidal UV lamp, Sylvania G 30T8 
located at 70 cms, which provides an intensity of irradiation of 116.6
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microwatts/cm2. A 60 second exposure was enough to kill the cells in 24 
to 48 hours.
Procedures - Primary FEK cells were seeded in multiwell plates3 (6 
wells per plate) in the amount of 1 X 10^ cells/well. When about 75% of 
the monolayer was formed ten-fold dilutions of stock EIAV were seeded in 
the respective wells in 13 replications. EIAV was allowed to adsorb for 
60 minutes at 37°C; then the excess virus was washed off with 
phosphate-buffered saline solution (PBS), pH 7.4, the monolayer refed, 
and the cells incubated at 37°C. Medium was changed every 3rd day and 
on day 12 the spent media was harvested and processed to determine the 
presence of EIAV antigen (p26) with an agar gel immunodiffusion test, 
using reagents prepared in our laboratory. If EIAV was not detected, 
the procedure was repeated until EIAV antigen was detected. Then, the
cell monolayers were irradiated for 60 seconds, and 1 ml of a solution
6 bcontaining 10 XC cells was added/well. The cells were fed with MEM
supplemented with 10% bovine fetal serurn̂ , and every 24 hours thereafter
with MEM supplemented with 3% bovine fetal serum. After four days, the
medium was removed and the monolayers fixed and stained with 2 mis of a
solution of 10% buffered formalin with 0.1% crystal violet for 5
minutes. The stained preparations were examined for plaques and/or
syncytia formation (cells containing five or more nuclei were scored as
syncytia); therefore, to minimize counting errors, ten randomly selected
fields (0.55 mm2) were counted per well using an inverted microscope
(Olympus) with a 10X ocular and 20X objective. The number of syncytia
counted per well was recorded as number of multinucleated cells per
virus dilution. A total of 30 control wells were studied which
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consisted of FEK cells not infected, but treated the same as the EIAV 
infected FEK cells
Test Statistics - The students t test was used to evaluate the 
results obtained, to determine first, differences in the number of 
syncytial cells counted within each one of the EIAV dilutions; second, 
differences in the mean number of syncytia counted among dilutions; 
third, differences in the number of syncytia counted in the control 
cells; fourth, differences in the number of syncytia counted in the test 
and control cells; in addition, the linear regression and correlation 
techniques were applied to the Y values (mean number of syncytia counted 
per EIAV dilution), to test for linear relationship with X (EIAV 
dilutions), and to measure the relative strength of the relationship 
between variables (correlation).
THE SYNCYTIA INFECTIVITY ASSAY (SIA)
Virus - The same EIAV stock already described was used in the SIA. 
Cell Cultures and Mediums - XC cells already described were used as 
indicator cells, and MEM*3, additioned of 10% or 3% bovine fetal serum 
used to start and to maintain the cells
The polycation DEAE-d was utilized to enhance virus penetration 
into the cells.
Procedure - XC cells were seeded in multi-well culture plates (24 
wells per plate)**, at a concentration of 1.5 X 10"* cells per well, and 
incubated at 37°C for 24 - 48 hours to form a layer of cells that was 
75% confluent. Growth medium was removed and the cells were treated 
with 25 micrograms of DEAE-d per ml, using 0.5 ml per well. After 60 
minutes at 37°C the DEAE-d was removed, and the cells were inoculated
with 0.1 ml of ten fold dilutions of EIAV stock, respectively, in 6 
replications per virus dilution. The virus was allowed to adsorb for 60 
minutes at 37°C; then the virus excess was washed off with PBS with a pH 
of 7.4, and the cells refed with MEM supplemented with 3% fetal calf 
serum. Finally, after 24 hours, the cells were washed twice with PBS, 
fixed and stained with a solution of 10% buffered formalin with 0.1% 
crystal violet. Polykaryocytes containing 5 or more nuclei were 
recorded as syncytia, and counted in 10 randomly selected fields per 
well using an inverted microscope (Olympus) with 10X ocular and 20X 
objective. As controls, six wells were treated with DEAE-d but received 
no EIAV, and six additional wells were left without any treatment 
(neither EIAV nor DEAE-d). The cells were fixed and stained and the 
polykaryocytes counted in the same way described for the test cells.
Test Statistics - The student t test was used to establish first, 
differences in the mean number of syncytia counted within each EIAV 
dilution; second, differences in the mean number of syncytia counted 
among the EIAV dilutions; third, the effect of DEAE-d treatment on EIAV 
infected and noninfected XC cells. Finally, the linear regression and 
correlation techniques were applied to the Y values (mean number of 
syncytia counted per EIAV dilution) to test for linear relationship with 
X (EIAV dilutions), and to measure the relative strength of the 
relationship between variables (correlation).
THE REVERSE PLAQUE ASSAY
Viruses - Equine infectious anemia virus stock No. 376 was used as 
in the previously described assays. In addition, a battery of viruses 
including VSV (New Jersey strain), equine herpes virus-1, equine
rhinovirus-1, equine adenovirus, and equine viral arteritis virus were 
assayed on FEK cells for their ability to induce plaque formation, and 
then be used as challenge virus for EIAV infected cells in an attempt to 
induce reverse plaque formation. Plaques were formed by equine herpes 
virus-1 and by vesicular stomatitis virus, but the other 3 viruses 
tested did not induce good plaque formation, then VSV was selected as 
challenge virus as it induced a better plaque formation.
Cell Culture and Mediums - Fibroblastic FEK cells were used as they 
are more susceptible to VSV, than epithelial cells. The cells were 
seeded and incubated in multi-well plates^ at 1 X 10"* cells/well and 
incubated for about 48 hours or until the monolayer was usually 
complete. The cells were fed with MEM supplemented with 10% bovine 
fetal serum^, and prepared as already described for the aforementioned
assays. But after EIAV infection, the cells were fed with a 2%
b bmethylcellulose overlay in MEM supplemented with 2% fetal calf serum .
Procedure - Fibroblastic FEK cells (IX 10"Vwell) were seeded in 
multi-well plates, and when the monolayer was complete it was infected 
with repetitive dilutions of EIA in the amount of 0.1 ml per well in 12 
replications. Six wells were not infected and acted as controls. After 
virus was added, it was allowed to adsorb for 30 minutes at 37°C, the 
plates being shaken at 10 minutes interval; then, the excess virus was 
washed off and the monolayers overlayed with methylcellulose, and 
incubated for 12 to 14 days, the medium being changed every 3 days. In 
addition, 12 replications of the titration were made by adding liquid 
medium after EIAV infection, instead of overlaying methylcellulose.
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After 12 to 14 days of incubation the wells were depleted of medium (the 
medium subsequently was assayed for EIAV p26 antigen by the AGID test), 
and VSV added at the multiplicity of infection of 2 to 5 plaque forming 
units (PFU)/cell, or in other trials 50 (PFU) per well. The virus was 
allowed to adsorb for 60 minutes, and then the plates were refed, and 
finally incubated for 15 to 20 hours at 37°C. At the end of this 
incubation, the monolayers were fixed and stained with 1.5 mis of a 
solution of 10% buffered formalin with 0.1% crystal violet per well for 
5 minutes. The plates were finally examined for plaques, or for reverse 
plaque formation.
RESULTS
THE MIXED CULTURE CYTOPATHOGENICITY ASSAY
The assay was carried out by a procedure described to titrate
murine leukemia viruses, but introducing some necessary modifications.
From the observation of the XC cells it was found that mitotic figures
are constantly found; in addition, many giant cells are seen with 2 to 3
nuclei. When XC cells were overlayed onto previously irradiated
uninfected and infected FEK cells the XC cells completely replaced FEK
cells without plaque formation, but with formation of giant syncytial
cells containing up to 18 nuclei (Table 1).
From Table 1 it can be seen that the number of polykaryocytes
counted was variable within each EIAV dilution, and at each replication;
accordingly, the statistical analysis indicated the following: (i)
there was no difference in the number of syncytia counted in the EIAV 
-1 -3dilutions 10 to 10 , but there was significant difference in the
-4 -6number of polykaryocytes counted in the dilution 10 to 10 (PS0.05);
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nevertheless, the counts were variable from one replication to 
another; (ii) there was not difference in the mean number of syncytia 
counted among the EIAV dilutions (PS0.05); (iii) there was a significant 
difference between the number of syncytia counted in the EIAV infected 
and noninfected (control), FEK cells (PS0.05); (iv) there was no true 
regression in the number of syncytia formed per EIAV dilution (see 
Figure 1). These results indicate that, the mixed culture 
cytopathogenicity assay is not useful to quantitate EIAV, in a similar 
manner as it has been used to titrate murine leukemia viruses.
THE SYNCYTIA INFECTIVITY ASSAY
Attempts were made to infect XC cells with EIAV without success. 
Table 2 shows the number of polykaryocytes counted per EIAV dilution in 
6 replications. The data from Table 2 indicate that the number of 
syncytia counted did not vary within each EIAV dilution; as a result, 
the statistical analysis yielded the following results: (i) there was
no significant difference in the number of syncytia counted within each 
one of the EIAV dilutions (PSJ0.05); (ii) there was no significant 
difference in the number of polykaryocytes counted among the EIAV 
dilutions (PS0.05); (iii) there was no true regression in the number of 
syncytia formed per EIAV dilution (see Figure 2); (iv) no syncytia were 
found in the control cells. Therefore, these results suggest that the 
SIA is not suitable for the quantitation of EIAV.
THE REVERSE PLAQUE ASSAY
Vesicular stomatitis virus was overlayed onto EIAV infected FEK 
cells, at the multiplicity of infection of 2 to 5 PFU/cell. It was 
observed that in the monolayers overlayed with methylcellulose, the
cells remained intact after infection giving a false impression of true 
heterologus interference between EIAV and VSV; on the contrary, the 
cells fed with liquid medium showed a large number of plaques, visible 
under the microscope only, or after staining 15 to 20 hours after VSV 
challenge. On the other hand, when 50 PFU of VSV per well were used, 
more discrete plaques were observed in the monolayers fed with liquid 
medium, but the monolayer was completely destroyed 36 hours after VSV 
infection. No difference was found with the control cells, which were 
also completely destroyed by VSV, and there was no reverse plaque 
formation. Consequently, these results indicate that EIAV does not 
interfere with the superinfection of FEK cells by VSV, and that no 
reverse plaques are formed in FEK cells monolayers previously infected 
with EIAV, and then challenged with VSV; therefore, the reverse plaque 
assay seems to be not suitable for the quantitation of EIAV using VSV as 
challenge virus.
DISCUSSION
THE MIXED CULTURE CYTOPATHOGENICITY ASSAY
When XC cells are overlayed onto non murine leukemia virus (FLV)
infected mouse embryo cells, the XC cells invade and completely replace
the monolayer; whereas, when overlayed onto FLV infected mouse embryo
cells, countable plaques are formed which is advantageously used to
15 16titrate murine leukemia viruses. ’ In our case, when XC cells were 
overlayed onto a complete monolayer of non-irradiated EIAV infected and 
noninfected cells, the XC cells did not grow probably due to lack of an 
attachment surface. On the contrary, when XC were overlayed onto 
previously irradiated EIAV infected and noninfected FEK cells, the XC
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cells completely replaced the FEK cells in 72 hours and showed syncytia
formation within hours of contact (syncytia from without).
The formation of syncytia is due to cell fusion, which can occur
independently of virus replication and can be induced by infective and
inactivated virus (cell fusion from without), or occurs in the later
stages of virus replicative cycle, following infection of cells with
27moderate or low doses of virus (fusion from within). However, the
exact mechanism of cell fusion is unknown, although much effort has been
27put into its elucidation during the past decade. Howe and Morgan have
shown that the envelope of Sendai virus is able to fuse with the plasma
membrane of erythrocytes; therefore, it is conceivable that an enveloped
virus particle in close association with the membrane of two different
cells, fuses with each permitting the formation of a cytoplasmic bridge
between the two. This hypothesis would explain the fusion from without
and within on the same bases, i.e., bridge formation between the virus
glycoproteins (gp90 and gp45 in EIAV) and normal cell membranes.
Equine infectious anemia virus does not appear to replicate on XC
cells, as we failed to detect the antigen in the cell culture
supernatants, even by trying to alter the XC cell membrane permeability
with DEAE-d; nevertheless, we found that more syncytia were formed at
-1 -3the lower EIAV dilutions (10 to 10 ). This finding suggests that the
syncytia formation would be mediated by EIAV external glycoproteins, 
that the cell fusion occurring would be due to cell fusion from without, 
and that syncytia formation is enhanced by placing XC cells in contact 
with virus producing cells. Finally, although syncytia formation seems 
to be induced by contact of EIAV and XC cells, the mixed culture
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cytopathogenicity assay is not adequate to titrate EIAV, because the
number of syncytia counted varied very much within each EIAV dilution
and with each replication and there was not true regression between the
mean number of syncytia counted and the virus dilutions. It is also
worthy of mention, that it is very difficult to maintain healthy FEK
cells in reduced growth areas, and that the need persists to find an
accurate and easy method to quantitate EIAV.
THE SYNCYTIA INFECTIVITY ASSAY (SIA)
Bovine leukemia virus (BLV), a type C leukemia virus is able to
induce rapid syncytia formation in monolayer cell cultures of
nontransformed cells from various species, a phenomenon that is
successfully used to quantitate the virus in a syncytia infectivity
20 21assay. * A similar technique was used in this study to try to
quantitate EIAV, but only a low number of syncytia were formed per EIAV
dilution, while in the SIA for BLV syncytia are formed in large amounts,
therefore allowing BLV titration, as the syncytia formation decreases as
BLV dilutions increase, giving a correlation between syncytium formation
20and the amount of BLV.
As it was previously mentioned, XC cells appear to not support the
growth of EIAV; thus, the syncytia formed after EIAV antigens and XC
cells membrane contact would be due to a cell membrane fusion from
20 21without, as it occurs in the SIA for BLV. ’ On the other hand, the 
treatment of the indicator cells (XC cells) with DEAE-d would not 
enhance the EIAV cell attachment and penetration; hence, the syncytia 
observed in the indicator cells would be produced by the fusion of two 
or more cell membranes by the outermost EIAV proteins (gp90 and gp45),
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or as a result of cell membrane injuries (by the viral antigens) which
join together to compensate for such injuries (cell membrane 
27dissolution, etc). As a result of this study, the titration of EIAV
cannot be obtained by the SIA, at least under the conditions of this
study; therefore, other research efforts should be considered in the
search of an easy and reliable system to titrate EIAV.
THE REVERSE PLAQUE ASSAY
Cells infected by more than one virus may support the normal
replication of them, or one virus may inhibit or enhance the
multiplication of other. Virus induced inhibition of viral replication
2 4is called "the interference phenomenon." Such phenomenon has been
advantageously utilized to titrate hog cholera virus (HCV), which is
noncytopathogenic, and the procedure has been known as "the reverse 
11 23 25plaque assay." 5 * The method is based on the complete resistance
of the HCV infected cells to superinfection by VSV. In this study, the 
aim was to determine whether the system could be used for EIAV 
titration. The results showed that when EIAV infected FEK cells which 
had been overlayed with methylcellulose were challenged with VSV, CPE 
did not occur giving the impression that EIAV actually interfered with 
cells superinfection with VSV; however, as the assay was also carried 
out using liquid medium (instead of methylcellulose), the monolayers 
showed extensive CPE 15 to 20 hours after VSV superinfection, and were 
completely destroyed after 36 hours. This finding indicated that EIAV 
infection does not interfere with superinfection of FEK cells with VSV. 
It was also concluded that VSV did not reach the cells (the cells fed 
with the methylcellulose overlay) because a thin film of the semisolid
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medium covered the monolayers. This film was not removed despite
several washes with PBS. In the reverse plaque assay as reported by 
25 23Fukusho al. and Laude , the reverse plaques were clearly visible
as intact cell colonies in the background of a disintegrated cell sheet,
and the relationship between virus concentration and the number of
25plaques was essentially linear.
It should be finally mentioned that 12 to 14 days were required for
EIA virus to grow before VSV challenge, and as already stated, it was
very difficult to keep FEK cells in good shape in a reduced growth area;
on the contrary, in the reverse plaque assay used to titrate HCV only 2
23 25or 4 days of virus incubation are required before VSV challenge. * 
Consequently, as EIAV does not protect FEK cells against superinfection 
with VSV (no reverse plaques are formed), the system as carried out in 
this study is not suitable for EIAV quantitation.
SUMMARY
A study was conducted to determine whether the mixed culture 
cytopathogenicity assay (XC cell assay), the syncytia infectivity assay 
(SIA), and the reverse plaque assay (RPA) would be suitable to 
quantitate equine infectious anemia virus.
The XC cell assay has been used to titrate several strains of 
murine leukemia virus, which do not induce cytopathogenic effect in 
tissue culture, but indirect syncytia and plaque formation occur in XC 
cells, when placed in contact with cells infected with murine leukemia 
virus. The SIA on the other hand, is utilized to quantitate bovine 
leukemia virus, as it is capable of inducing rapid syncytia formation in 
monolayer cell cultures of nontransformed cells from various species.
Finally, the RPA has been used to titrate some noncytopathogenic 
viruses, like hog cholera virus and Sindbis virus, which induce a 
transient refractory state of the cell to superinfection with vesicular 
stomatitis virus. Challenge of cells previously infected with hog 
cholera virus, results in the formation of islands of cells (reverse 
plaques) surrounded by disintegrated cell debris.
The results of this study indicate that none of these techniques is 
accurate to quantitate EIAV, under the conditions utilized to carry out 
the assays.
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TABLE 1. Number of syncytia counted per EIAV dilution in the XC cell
assay
EIAV dilutions
Replications 10 ^ io -2 io -3 10~4 IO-5 10-6
Cell
controls
1 1 1 0 1 0 0 0 4 3
2 5 3 0 4 3 0 0 4 2
3 18 12 7 6 4 7 3 5 1
4 3 3 5 4 1 3 4 4 0
5 8 7 7 1 4 5 5 4
6 4 4 2 6 4 2 4 1
7 4 4 4 2 7 5 5 1
8 3 4 5 2 1 0 4 3
9 4 2 4 8 5 2 5 0
10 6 3 4 4 3 1 4 4
11 8 2 3 2 2 2 4 1
12 6 0 2 4 0 1 6 0
13 4 2 1 3 1 2 3 0
X 5.7 3.6 3.4 3.2 2.7 2.3
SD 4.2 3.0 2.3 1.6 2.1 2.1
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p—i1o«-H io -2 -3 -4 10 J 10 * io " 5 io " 6
1 5 2 3 9 2 7
2 1 3 4 0 1 0
3 3 1 2 4 6 2
4 2 1 1 3 4 3
5 0 3 1 1 2 2
6 3 2 4 3 2 0
X
SD
2.3 2.0 2.5 3.3 2.8 2.3
1.75 0.8 1.3 3.1 1.8 2.6
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FIGURE 1. Mean number of syncytia counted per EIAV dilution in the mixed culture cytopathogenicity assay 
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FIGURE 2. Mean number of syncytia counted per EIAV dilution in the syncytia infectivity assay and 
regression line (r = regression coefficient). 115
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